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The human colon hosts a diverse and metabolically complex community of microorganisms. 
While the colonic microbiome has long been suggested to contribute to the development of 
colorectal cancer (CRC), a definitive link has not been made. In this thesis, studies that 
define the bacterial associations of CRC in the genetically normal host (sporadic CRC) and 
the host predisposed to early colon carcinogenesis [familial adenomatous polyposis (FAP)] 
are presented.  We demonstrate for the first time that bacterial biofilms are a common 
feature of many sporadic colorectal cancers, one of the leading malignancies in the United 
States and abroad. Colon biofilms, dense communities of bacteria encased in a mucus matrix 
that contact the colon epithelial cells, are a nearly universal feature of sporadic right colon 
tumors with broad extension over the right colon in the tumor host. Most remarkably, 
biofilm presence correlates with bacterial tissue invasion and a change in tissue biology 
including changes in oncogenic signaling pathways [E-cadherin, IL-6 and signal transducer 
and activator of transcription 3 (Stat3)], enhanced polyamine metabolites and increased 
cellular proliferation, changes capable of promoting oncogenic transformation.  Deep 
sequencing revealed that biofilm communities on paired normal mucosa cluster with tumor 
microbiomes but lack distinct taxa differences. In striking contrast, biofilms were detected 
throughout the colons of individuals with the hereditary CRC condition (FAP) and lacked 
the diverse composition of biofilms associated with sporadic CRC. Namely, biofilms of FAP 
patients are comprised largely of pathogenic subtypes of Escherichia coli (pks+) and Bacteroides 
fragilis (bft+).  This work introduces a new concept whereby the microbial community 
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Each year, approximately 1.2 million individuals are diagnosed with colon cancer worldwide 
[1]. As the second leading cancer affecting both men and women, colorectal cancer (CRC) 
claims the lives of over 600,000 individuals annually [1].  Greater than 90% of CRC cases are 
spontaneous, occurring in people with little or no family history of the disease. Once 
thought to be a cancer predominantly afflicting the Western world, incidence rates of CRC 
are rapidly increasing in countries that have historically been considered low risk, including 
South America, eastern Asia, and Eastern Europe [1].  This trend has been attributed to 
changes in dietary patterns, along with decreased physical activity, leading to a rise in obesity 
within these populations [2,3]. As a prominent public health threat, potential contributions 
to the development of CRC have been the focus of intense study.  Colorectal carcinomas 
usually begin as benign tumors, called polyps or adenomas, which can develop anywhere 
along the colon from the epithelial cells lining the mucosa. Typically over a period of 10 or 
more years, some polyps become cancers.  Importantly, however, colon cancer can be fully 
prevented by early detection and removal of polyps. This progression from normal 
epithelium to adenoma to adenocarcinoma has been well characterized by Fearon and 
Vogelstein to involve the cumulative accumulation of genetic mutations [4]. The proposed 
classes of optimal target genes include tumor suppressors and oncogenes, along with 
mismatch repair genes. Common examples include APC (a tumor-supressor gene), KRAS 
(an oncogene), and MLH1 and MLH2 (mismatch repair genes) [4,5].  While there is general 
consensus about the stepwise transition to colorectal carcinoma, the initiating mechanism(s) 
remain unclear. 
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The notion that the endogenous enteric microbiome contributes to the etiopathogenesis of 
colon cancer has been proposed for decades. The human gastrointestinal (GI) tract is 
colonized by a vast and complex community of microorganisms totaling approximately 1013 
bacteria composed of over 500 microbial species [6]. The commensal intestinal microbiota 
outnumbers human cells nine to one, and perhaps more impressively, their collective genes 
outnumber that of their human host 100 to one. The influences of this large microbial 
community are immense. The colon is colonized soon after birth, facilitating the essential 
roles played by the colon microbiota in host physiology, including mucosal immune 
development, regulation of cell proliferation and modulation of gene expression in host 
epithelial cells [7,8]. Other beneficial functions of the metabolically complex microbiome 
include providing usable forms of nutrients as a byproduct of metabolism and protection 
against exogenous pathogens. In the healthy colon, the microbiota interactions with the host 
are at homeostasis; however, intrinsic or extrinsic factors can cause perturbations, leading to 
abnormalities in microbiome composition or function that have been associated with several 
diseases, including inflammatory bowel disease (IBD) and colon cancer [9,10].  
The entirety of the healthy human colon is covered by a mucus layer that consists of an 
inner gel-like layer and a loose outer layer, both primarily composed of a secreted network of 
highly glycosylated MUC2 mucins. Among the family of mucin genes expressed in the 
human colon, the gene product of MUCB has also been detected in minor quantities at the 
base of the crypt [11]. In addition, MUC5AC and MUC6 have been associated with 
colorectal adenomas and ulcerative colitis [12]. The outer mucus layer serves as a 
semipermeable network providing a habitat for commensal bacteria to reside in, while the 
inner gel-like mucus layer acts as a physical barrier excluding bacteria from direct contact 
with the epithelium [13]. It is likely that bacteria transiently penetrate the inner mucus barrier 
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in a healthy state; however, they are thought to be cleared quickly through host immune 
responses [13]. The inner mucus layer ranges in width from 30 to 170 μm in the human 
colon, increasing in depth from the ascending to the descending colon [14].  Bacteria mainly 
colonize two major niches within the human colon: the lumen and the outer mucus layer. 
Characterization of these distinct microbial communities has been the focus of a series of 
recent studies [6,15-17]. The distinction between these communities is important, as the 
microbial milieu in these two ecological niches may contribute differently to the etiology of 
disease. It is well accepted that microbial dysbiosis (an imbalance of the microbiota) with 
bacterial invasion and persistence in the inner mucus layer (biofilm formation), contributes 
to the development or progression of IBD [9,18,19].  Massive bacterial biofilms within the 
normally empty mucus layer, constituting invasions of greater than 109 bacteria/ml, were 
identified in 94% of Ulcerative Colitis patients, 98% of Crohn’s Disease patients, and 78% 
of self-limiting colitis patients, compared to just 11% in controls [19]. The phylum-level 16S 
profiles were observed to involve a shift in major populations, most notably an increase in 
Proteobacteria and a decrease in Firmicutes and Bacteroidetes [18].  IBD is associated with 
an increased risk for the development of GI malignancies. While the development of CRC in 
the setting of IBD involves many of the same genetic mutations as the stepwise transition to 
sporadic CRC, the timing and frequency of these mutations often differ [20,21]. 
Furthermore, chronic colitis-associated CRC tends to be macroscopically heterogeneous 
compared with sporadic CRC and arises from flat dysplastic tissue rather than distinct polyps 
[21]. This stresses the importance of the major focus of this dissertation work, characterizing 
the microbial-epithelial interactions in various CRC disease states, analyses that have been 
less detailed to date [17,22,23].  
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1.2 Mechanisms of Bacterial Induced Oncogenesis  
A significant amount of effort has been employed to determine the mechanisms of 
microbially induced oncogenesis. Proposed mechanisms include the inhibition, alteration or 
exacerbation of normal host responses such as apoptosis, inflammation and cellular 
proliferation (CHAPTER 2).  Alternatively, bacteria may also promote cancer through 
production of secondary metabolites (CHAPTER 3), or direct effects on cell 
transformation through the production of oncogenic toxins (CHAPTER 4).  An overview 
of the mechanisms of bacterial initiation or progression of oncogenesis is shown in Figure 
1.1. 
Chronic Inflammation 
The association between inflammation and tumorigenesis has been appreciated since 1863 
when Rudolph Virchow hypothesized that cancer developed from sites of chronic 
inflammation, termed ‘the chronic irritation hypothesis’ [24].  Today, the connection 
between inflammation and cancer is well established; however, the mechanisms and 
pathways are not fully characterized.  Infection triggers inflammation as a means to 
effectively combat an invading pathogen.  Polymorphonuclear phagocytes are typically the 
first cells recruited to the site of infection, which serve as potent producers of 
proinflammatory cytokines and chemokines that amplify the response by recruiting more 
immune cells [25,26]. These cells produce an abundance of reactive oxygen species which 
can damage lipids, protein, and DNA leading to increased mutations in proliferating cells 
and ultimately alterations in cell turnover and death [25-28].  
While bacterial infection was once thought of as an acute condition, it is clear that many 
bacteria are able to persist in the host and lead to chronic infections accompanied by 
inflammation. Study of the molecular mechanisms that link chronic infections to 
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inflammation and cancer is an area of intense investigation.   Persistent generation of 
microbially induced inflammation mediators such as TNF-α, IL-1, or even 
lipopolysaccharide on its own can lead to the induction of the NF- κB family of 
transcription factors, which have been shown to play a role in inflammation-driven 
carcinogenesis [27]. Some of the genes targeted are inflammatory cytokines including IL-6, 
IL-1β, and vascular endothelial growth factor (VEGF), which lead to a positive feedback 
loop of continuing inflammation [25-27]. Observations using human sera and tissue 
(including data presented in CHAPTER 2), as well as strong evidence through experimental 
mouse models have shown that IL-6 promotes survival, proliferation and progression to 
CRC in an inflammatory setting via the signal transducer pSTAT3 [29-31]. In addition, 
antiapoptotic genes, such as those of the Bcl2 family, are upregulated by NF-κB, preventing 
routine cell turnover.  Furthermore, expression of genes involved in cell-cycle regulation is 
altered (e.g., cyclins are upregulated and cell cycle inhibitors are downregulated).  Ultimately, 
NF-κB plays a key role in inflammation-driven tumor development by generating an 
environment that promotes mutations and simultaneously prevents damaged cells from 
undergoing apoptosis, both key features of cancerous cells [25-28].   
Reactive oxygen species (ROS) and nitric oxide (NO) are also generated by inflamed 
epithelial cells under the stress of bacterial toxin exposure or chronic bacterial infection 
[28,32].  These molecules play important roles in the initiation and progression of 
carcinogenesis by directly altering DNA, leading to mutations, deletions and chromosomal 
instability; if left unrepaired, these can lead to carcinogenesis [25,33].  In addition to direct 
effects on DNA, reactive species can influence cytoplasmic and nuclear signal transduction 
pathways. For example, reactive oxygen species (ROS) can direct cell proliferation and 
inhibit apoptosis through activation of the transcription factors MAPK (mitogen-activated 
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protein kinases), AP-1 (activator protein 1), and NF-κB [33].  Persistent asymptomatic 
bacterial infection of the colon in which the inner mucus layer is penetrated is proposed as 
capable of inducing chronic inflammation resulting in a cascade of diverse and complex 
events that compound to generate a procarcinogenic microenvironment.  Bacterial breach of 
the mucus layer, and subsequent biofilm formation on the epithelium, is investigated in 
CHAPTER 2 of this dissertation.  
Oncogenic Bacterial Metabolites and Toxins  
In addition to the indirect influences of chronic bacterial infection, there are also direct 
bacterial mechanisms of oncogenesis.  Diets that are high in fat and protein provide 
substrates for microbial production of pro-carcinogenic products such as secondary bile 
acids, ammonia and polyamines. Strong evidence for the microbial production of polyamines 
on biofilm-covered tumor tissues is described in CHAPTER 3.  Through their metabolically 
complex processes, bacteria also produce reactive species such as the derivatives of 
molecular oxygen including superoxide, hydrogen peroxide, and hydroxyl radicals [33,34]. 
These free radicals contribute to genomic instability by the mechanisms discussed above.  
 Alternatively, several bacterial toxins have been identified that are predicted to be 
carcinogenic. These toxins have the capacity to modify host physiology leading either to 
direct DNA damage, augmentation of cellular proliferation and/or disruption of cellular 
differentiation and apoptosis [34].  One thoroughly studied example is CagA of Helicobacter 
pylori, which is considered to be the most important risk factor that links H. pylori infection to 
the development of gastric cancer [35,36]. CagA binds the cellular tyrosine phosphatase, 
SHP2, leading to modulation of cell structure [28].  It has also been shown to target multiple 
host proteins that regulate inflammation, and several studies suggest an ability to activate 
NF-κB and β-catenin signaling [37-40]. Recently, CagA was associated directly with a tumor 
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suppressor pathway when it was shown to usurp the tumor suppressor apoptosis-stimulating 
protein of p53 (ASPP2) and modify its activity thus promoting cell survival [41]. Strains of 
H. pylori expressing active VacA are associated with an increased risk of gastric cancer [42].  
 Another example of a bacterial toxin is the cytolethal distending toxin (CDT).  This 
genotoxin is produced by several bacteria including selected strains of Escherichia coli, 
Actinobacillus actinomycetemcomitans, Campylobacter jejuni, Shigella spp., Salmonella spp., Helicobacter 
hepaticus, Helicobacter cinaedi, as well as other enterohepatic Helicobacter spp. [43].  CDT is 
composed of three subunits, one of which, CdtB, functions similar to mammalian DNase 
directly damaging host DNA [44].  Another CRC genotoxin family of interest, investigated 
in CHAPTER 3, can be found within the polyketide synthase (PKS) genotoxic island of E. 
coli. Recent studies have shown that this island encodes a hybrid peptide-polyketide, 
colibactin, capable of directly inducing DNA double strand breaks both in vitro and in vivo 
[45,46]. Further, deletion of the genotoxic PKS island from an E. coli strain diminished its 
oncogenic potential [47,48]. In addition to the toxins mentioned above, the microbial 
community contains a repertoire of toxins, listed in Table 1.1, proposed to have oncogenic 
abilities. Of this group, toxins produced by E. coli, Salmonella spp., Shigella spp. or Bacteroides 
fragilis are potential contributors within the microbiota to CRC pathogenesis. One consistent 
feature of these bacterial carcinogenic mechanisms is that through either direct or indirect 
methods they interfere with key eukaryotic processes. 
 
1.3 APC Min model of Bacteroides fragilis-induced CRC 
One of the more compelling pieces of evidence displaying a direct link between an infectious 
bacterial agent in the induction of colorectal cancer lies with the murine models of 
enterotoxigenic Bacteroides fragilis (ETBF) infection.  The genus Bacteroides is one of the most 
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numerically prominent members of the intestinal microbial flora. One species in particular, 
Bacteroides fragilis, is a Gram-negative obligate anaerobe and common symbiote colonizing 
nearly all humans.  However, B. fragilis is also an important opportunistic pathogen, as it is 
the most common anaerobe isolated from clinical infections despite comprising only a small 
part (<1-2%) of the total microbiota [49,50]. Long recognized for roles in intestinal 
infections, more recently the molecular subtype, enterotoxigenic Bacteroides fragilis (ETBF), 
was revealed to induce colitis in wild-type C57Bl/6 mice and promote oncogenic 
transformation in multiple intestinal neoplasia (Min) mice (a murine intestinal cancer model) 
[51,52]. B. fragilis consists of two molecular subtypes termed nontoxigenic B. fragilis (NTBF) 
and ETBF.  NTBF is proposed to be a probiotic organism, serving a crucial role in immune 
development and providing the host with usable forms of dietary products [7]. In contrast, 
ETBF has been identified as a cause of inflammatory diarrheal disease in animals and 
humans, and has also been suggested to be associated with active IBD and CRC [53-56].  
Interestingly, a recent study by Zitomerskey et al found that ETBF carriage is potentially 
quite common in the US population, as they detected ETBF in 40% (6 out of 15) of healthy 
asymptomatic individuals between 31 and 66 years of age in Boston (MA,USA) [57].    
To date, no ETBF strains have been fully sequenced.  However, through identification and 
sequencing of a transposon-flanked pathogenicity island, ETBF was determined to encode a 
20 kDa zinc-dependent metalloprotease termed Bacteroides fragilis toxin (BFT) [58,59].  BFT is 
the only known virulence factor of ETBF, and all strains harbor one of three highly related 
bft isoforms (bft-1, bft-2, or bft-3) present on the B. fragilis chromosome. All molecular 
isoforms are capable of exhibiting biological activity; however the relationship between 
isoform and disease severity is not yet known.  BFT binds to a unknown colonic epithelial 
cell receptor, triggering rapid cleavage of the tumor suppressor protein E-cadherin, which, in 
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turn, frees its associated β-catenin, allowing its nuclear localization [60]. The subsequent 
expression of the β-catenin/Wnt signaling pathway leads to an increase in colonic epithelial 
cell proliferation. BFT also stimulates additional signaling pathways through NF-κB. While 
the precise contribution of the plethora of colonic epithelial cell signaling triggered by BFT 
to ETBF pathogenesis remains unknown, one clear biologic outcome is the recruitment and 
activation of inflammatory cells, as well as epithelial cell secretion of proinflammatory 
cytokines and ROS production [32,61,62]. A recent study by our group demonstrated that 
ETBF induces a rapid-onset acute symptomatic colitis, followed by chronic subclinical 
colonic inflammation and hyperplasia in specific pathogen-free (SPF) WT C57Bl/6 mice. 
Unique to this model is the ability of ETBF to persistently colonize the mice for an extended 
period of time after a single oral exposure to ETBF; in this study mice carried out to 16 
months exhibited low-level colitis [52]. The acute ETBF murine colitis mimics the 
inflammatory diarrhea detected in humans with ETBF infection, whereas the long-term 
murine colonization is analogous to what is observed in ETBF colonization in the human 
population, suggesting that ETBF carriers may be susceptible to asymptomatic ETBF-
induced colitis.  
The pro-oncogenic cellular signaling induced by BFT in concert with the persistent chronic 
inflammation induced by ETBF in WT mice, suggest that ETBF is an oncogenic bacterium.  
This was recently tested by our group using the APC Min mouse strain, a well-established 
cancer model in which loss of a single copy of the Apc gene predisposes mice to the 
development of numerous tumors in the small intestine when the second allele 
spontaneously mutates [63]. However, importantly for this animal model of bacterial-
induced carcinogenesis, adenomas are primarily observed in the small intestine and not in 
the colon [64].  APC is a multidomain tumor suppressor protein that binds to and promotes 
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proteosomal degradation of β-catenin to regulate downstream Wnt signaling [64]. Loss or 
mutation of the Apc gene is the cause of the inherited disease familial adenomatous 
polyposis (FAP), and occurs in virtually all sporadic colon cancers [65].  By 4 months of age, 
sham APC Min mice developed an average of one to three tumors in the colon. By contrast, 
APC Min mice colonized with ETBF developed chronic asymptomatic colitis, with colon 
tumor foci detected as early as 1 week postinoculation.  At 1 month of age, a marked 
increase in colon tumor formation (~12 tumors/mouse on average) occurs predominantly in 
the distal colon of ETBF-colonized mice.  By contrast, Min mice colonized with NTBF did 
not exhibit colon tumors in excess of the sham mice. ETBF induces rapid activation of Stat3 
both in the colonic epithelial cells, which are the targets of transformation in the colon, and 
in a subset of mucosal immune cells. Stat3 activation is required for Th17 cell development 
and, consistent with this, ETBF induces a rapid mucosal Th17 inflammatory response within 
1 week of colonization. Colon tumors induced by ETBF also have a marked increase in Stat3 
activation.  Furthermore, excess tumor formation is significantly inhibited by administration 
of IL-17 blocking antibody, indicating that IL-17 is necessary for tumorigenesis in this model 
[51].  These studies suggest that persistent long-term colonization with ETBF may induce 
chronic colonic inflammation, with the potential for oncogenic transformation [51,52]. 
Furthermore, while Th17 inflammatory responses typically help the host control bacterial 
and fungal infection, the ETBF murine model demonstrates that endogenous Th17 
responses can yield oncogenesis in the colon, a result supported by additional murine and 





1.4 Other animal models of bacterial influences on CRC     
Animal models of bacterial driven oncogenesis have proven to be valuable tools in 
elucidating the link between microbes and CRC.  Genetic knockout, germfree, and 
chemically-induced mouse models have been developed and extensively used in studies 
connecting bacteria and CRC.  The APC Min model previously mentioned was the first 
mutant murine model for colon cancer and is an important tool, given the importance of 
inactivation of the Apc gene in the initiation of sporadic CRC.  This initial APC Min mutant, 
carrying a truncation at codon 850 of the Apc gene, was identified among a colony of mice 
following random ethylnitrosourea mutagenesis [71].  Utilizing gene knockout technology, 
alternative Apc mutants have subsequently been constructed including mouse strains with 
truncations at codon 716 and 1638 that also develop polyps [64,72].  There are several 
additional genetically engineered models of intestinal neoplasia, extensively covered in a 
review by Taketo and Edelmann, including single knockouts of Muc2, IL-10, Smad3, and 
Gαi2 ; and double knockouts of APC with Smad4, TCRβ with p53, Gpx1 with Gpx2, Tgfβ-1 
with Rag2 [73-81]. In the absence of intestinal microbiota, under germfree conditions, Il10-/-, 
Tcrb-/-; Trp53-/-; Gpx1-/-; Gpx2-/-and Tgfb-/-; Rag2-/- mice all showed decreased or completely 
inhibited tumor formation [79-85]. Together, these studies indicate a role for the intestinal 
microbiota in development of inflammation and neoplasia.  Mixed results have been 
reported in germfree APC Min mice. While Dove et al. noted a twofold decreased tumor 
load in the medial small intestine, they did not see a significant overall decrease in tumors 
[83]. By contrast, a recent study by Li et al. found a significant decrease of tumor load in both 
the small intestine and the colon. Furthermore, they identify two pathways triggered by 
microbiota, c-Jun/JNK and STAT3, which act to enhance tumor formation [84].      
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Mouse models of chemically induced colitis have also been used in studies to address the 
bacterial involvement in colitis and tumorigenesis. The most commonly used agents are 
azoxymethane (AOM) and dextran sulfate sodium (DSS).  A recent study by Uronis et al. 
found that IL10-knockout mice that were colonized with complex microbiota and exposed 
to AOM developed tumors; however, germfree conditions abolished tumor formation [86]. 
It was further shown that conventional IL-10/MyD88 double knockout mice showed no 
signs of tumor development upon treatment with AOM, suggesting that microbially-induced 
tumorigenesis in this system was dependent on the TLR/MyD88 pathway [86].  Johansson et 
al. showed that bacteria penetrate the inner mucus layer before inflammation is observed in 
the DSS colitis model, suggesting that invasion of the protective inner mucus layer and 
subsequent bacterial contact with the epithelium triggers the host immune response and 
inflammation [87].  Further studies have shown that DSS-induced colitis can be ameliorated 
under germ free conditions, indicating that the presence of microbiota facilitates DSS colitis 
[88].  A more recent study by Elinov et al. further supports the role of intestinal flora in the 
DSS-induced inflammation. Using mice deficient in the NLRP6 inflammasome, they showed 
that the resulting altered microbiota, characterized by increased levels of Bacteroidetes, led 
to an increased recruitment of inflammatory cells and worsened colitis upon DSS exposure 
when compared to wild-type mice [89].  This report, among others, emphasizes that the 
microbiota composition is shaped not only by diet, but by the host immune make-up, 
suggesting that human host polymorphisms modulating the inflammatory response may be 
important contributors to the influence of the microbiota on CRC pathogenesis [47,86,90-
92]. Furthermore, several studies have shown that antibiotic treatment is capable of blocking 
colitis in the murine DSS colitis model [93-95]. Under germ-free conditions, DSS treatment 
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alone, however, is able to induce a slight inflammatory cell infiltration and edema, but 
without tumor induction [96].  
While abundant data implicate the aggregate microbiome as a cofactor in colon tumor 
development, individual pathogens thought to promote colonic tumorigenesis have also 
been investigated using animal models.  A study by Ellmerich and colleagues showed that 
Streptococcus bovis, long associated with colon cancer through epidemiological studies, is 
capable of markedly increasing the production of inflammatory cytokines and aberrant crypt 
foci in the colonic mucosa of rats through exposure to S. bovis cell wall antigens [97]. This 
study, however, lacked controls to demonstrate that the response was specific to S. bovis cell 
wall antigens. Furthermore, it is important to mention that the strain utilized in this study 
was later classified as S. bovis biotype II/1 (Streptococcus Infantarius subsp Infantarius) which 
shows a less convincing link to human CRC when compared with biotype I, a topic 
thoroughly covered in a recent review by Boleij and Tjalsma [98].  Another suspect, 
Helicobacter hepaticus, colonizes the liver and colon of several mouse strains and has been 
linked to hepatitis, chronic colitis and CRC, well-discussed in a recent review by Fox et al. 
[99] . It was recently shown that H. hepaticus triggers nitric oxide and TNF-α production, 
leading to inflammation and carcinogenesis in Rag2-deficient mice, implicating innate 
immune response induced by H. hepaticus as carcinogenic [100].  A subsequent study utilized 
transcriptional profiling of H. hepaticus-infected Rag2-knockout mice to reveal that colon and 
liver tissues exhibited different stress responses to infection.  The colon was found to have a 
significant upregulation of genes involved in the generation of reactive species, while genes 
involved in DNA repair showed lower expression: this was directly contrasted with the liver, 
which showed upregulation of all major DNA repair pathways during infection [101].  These 
findings support the role of H. hepaticus in inflammation-induced carcinogenesis, and also 
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leads to interesting insights into the complexity of tissue specific microbial pathophysiology. 
Similarly the colon microbiota has been thought to play a role in the progression of certain 
diseases, such as HIV and HCV, both of which are conditions associated with an increased 
risk of cancer [102,103]. Other studies show that certain strains of Enterococcus faecalis produce 
extracellular superoxide and hydrogen peroxide that induces aneuploidy and tetraploidy in 
colonic epithelial cells [104,105]. E. faecalis also encodes a metalloprotease, GelE, that 
contributes to the development of colitis, dysplasia and adenocarcinoma in germ-free IL10-
deficient mice [82,106]. However, to date, a link between E. faecalis and human CRC has not 
been identified [107].   
In recent years, Fusobacterium nucleatum has become a putative candidate for contributing to 
CRC oncogenesis. Increased abundance of Fusobacterium spp. (most often F. nucleatum) is 
associated with CRC as determined through sequence analysis [23,108-110].  Recent 
experimental evidence, revealed the oncogenic potential of F. nucleatum. An IBD isolate of F. 
nucleatum induced an increase in small bowel tumors and colon adenomas in APC Min 
mice[109].  Similar to the findings in humans, F. nucleatum was enriched on tumor tissue 
compared to non-tumor tissue within an individual mouse.   Furthermore, the authors 
identified a pro-inflammatory immune signature shared by Fusobacterium-associated APC Min 
tumors and human tumors with high Fusobacterium abundance, defined as >25% of 
sequence reads.   These results were published in the same issue as the complementary data 
presented by Rubinstein et al. [111].  The authors suggest that a surface adhesion, FadA, 
confers virulence traits that could contribute to the carcinogenic properties of the organism.  
Specifically, FadA was found to facilitate the adherence to and invasion of colon carcinoma 
cell lines as well as tumors in xenograft mice resulting in increased cell proliferation. The 
authors further show that FadA binds to a specific extracellular domain of E-cadherin 
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triggering the β-catenin/Wnt signaling cascade and differentially promotes inflammation and 
oncogenesis. While the association between Fusobacterium and CRC tumors has been well 
established, fadA gene levels were also found to be increased in the colon tissues from 
individuals with CRC or adenomas compared to healthy subjects.  
Another well-studied bacterial agent of interest is Citrobacter rodentium, which is known to 
induce self-limiting colitis, epithelial cell proliferation, and tumorigenesis in the murine colon 
[112]. C. rodentium is not a human pathogen, but is considered the mouse homolog of human 
attaching and effacing E. coli strains, which are yet another proposed procarcinogenic 
species. Early studies found that C. rodentium infection increases the carcinogenic effect of 
1,2-dimethylhydrazine (DMH) treatment in NIH Swiss mice [113]. Later, a study revealed 
that C. rodentium infection leads to cytokinetic alterations and is sufficient to promote colon 
tumor development in APC Min mice [114].  Maddocks et al. reported that human attaching 
and effacing enteropathogenic E. coli (EPEC) downregulate DNA mismatch repair genes 
and provided preliminary data identifying these bacteria in human CRC [115]. A publication 
by Arthur et al. showed that tightly adherent E. coli strains harboring the PKS genotoxic 
island were able to induce tumor formation in AOM-treated IL10-deficient mice under 
germfree conditions [47]. The authors further showed that conventionally housed IL10-
deficient mice developed an altered microbiome in association with colitis that occurred in 
100% of the IL-10 deficient mice. Importantly, they showed that inflammation, not the 
carcinogen AOM, modifies the microbiota structure with emergence of potential 
procarcinogenic phyla. Further, a specific microbial virulence factor (the PKS island), not 
inflammation alone, was required for the microbially–induced carcinogenesis in this model.  
This study stresses the interplay between specific carcinogenic species, the microbial 
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community and the host. Consideration of these multifactorial influences is important when 
transitioning to studies concerning microbial involvement in human CRC.            
 
1.5 Human studies  
 
Despite a long quest, direct links between the bacterial microbiome and CRC in humans are 
not yet established. Culture-based, observational or case-control studies largely focusing on 
fecal analyses from patients with CRC and healthy control patients have suggested that 
Bacteriodes, Streptococcus gallolyticus subsp gallolyticus (previously known as S. bovis biotype I), E. 
coli and Enterococcus, among others may be associated with development of CRC. Particularly 
notable over time has been the association of Streptoccous gallolyticus endocarditis and/or 
bacteremia with a high likelihood of having an underlying gastrointestinal tract malignancy, 
most commonly CRC [116-122].  Clostridium septicum aortitis and/or bacteremia have also 
been suggested as indicators of gastrointestinal malignancy [123]. Culture-based human 
studies combined with recent experimental mechanistic studies have provided the greatest 
support for potential roles for ETBF, Streptococcus gallolyticus, Fusobacterium nucleatium, 
enteroadherent E. coli and E. coli possessing the PKS island in human CRC 
[47,55,111,115,120].  
Molecular approaches, in particular the advent of next generation sequencing techniques, 
have facilitated studies to examine more comprehensively the microbial associations of CRC 
(Table 1.2). These approaches enhance culture-based methods because they allow detection 
of ‘noncultivatible’ microbes. Overall, available data suggest that the tumor-associated 
microbiome differs from that detected on matched normal tissue in the same patient. 
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Further the fecal microbiome of CRC patients appears to differ from that associated with 
their tumor and also from the fecal microbiome of healthy volunteers [124,125]. A wide  
range of bacteria have been reported as enriched in tumor tissue samples including E. coli, 
Proteobacteria (especially Enterobacteriaceae), Bacteroides spp., Prevotella spp., Streptococcus spp., 
Peptostreptococcus spp., Enterococcus spp. and Fusobacterium spp. [22,23,108,110,126]. However, 
the differences detected between sample groups varies among studies without clear patterns 
yet detected that might be useful, for example, to identify an individual at risk for or with 
CRC. The methodologic differences, varying sample types analyzed, varying populations 
studied as well as limited patient data provided makes differences among the studies difficult 
to interpret. Two studies from 2013, representing the largest set of CRC and matched 
normal tissue samples analyzed to date, identified a predominance of Fusobacterium spp. (F. 
nucleatum and other Fusobacterium spp.) associated with CRC as compared to adjacent normal 
tissue [23,108]. Of note, no healthy control populations were included in either study. Most 
studies have focused on patients with CRC; however, to begin to implicate bacteria in the 
pathogenesis of CRC, it is important to determine bacterial associations of colonic 
adenomas, precursors of CRC. Similar studies considering the unique pathogenic 
associations discussed earlier for IBD (see introduction) would also be helpful. In the one 
molecular study evaluating adenomas available to date, the bacterial population distributions 
also differed between adenoma and control patients when rectal biopsies of normal tissue 
were compared by 16S rRNA sequence analysis [17]. It is clear that additional studies are 
needed not only to delineate the microbial populations associated with CRC compared to 
diverse control populations, but also to understand how the microbial populations may 
relate to disease outcome and may contribute to the pathogenesis of CRC.  
 
 19 
1.6 Thesis Aims 
The overall goal of this thesis was to systematically characterize the bacterial community 
adherent to and directly adjacent to the colon epithelium of various pathological disease 
states:  sporadic CRC (adenoma and carcinoma), familial CRC (adenomas from patients with 
familial adenomatous polyposis), as well as healthy subjects.  This was accomplished through 
the following specific aims.   
 
Specific Aim 1: Identify the composition and spatial arrangement of the bacterial 
community directly adherent to the colonic epithelium of sporadic colorectal cancer 
patients and healthy control subjects. 
 
Specific Aim 2: Determine the metabolomic contribution of the bacterial biofilm 
community identified on select sporadic colorectal cancers.   
 
Specific Aim 3: Characterize the composition and spatial arrangement of the 
bacterial community directly adherent to the colonic epithelium of familial 














Figure 1.1 Overview of tissue- and cell-level mechanisms of bacterial oncogenesis. (A) In 
the healthy human colon, the inner mucus layer serves as a physical barrier separating the 
mucosal epithelium from luminal contents. The mucus layer is further protected through 
epithelial cell secretion of antimicrobial peptides and plasma cell secretion of IgA. This 
spatial segregation largely maintains the host–microbe homeostasis; nevertheless, bacterial 
invasion of the inner mucus layer does occur. (B) It is this perturbation that facilitates direct 
interactions between microbes and host cells, resulting in pathology. The precise 
mechanisms by which the bacterial community may induce oncogenesis when invading the 
inner mucus layer are, as yet, uncertain. (C & D) By contrast, for select bacteria for which 
preliminary epidemiologic data suggest an association with some human colorectal cancer, 
linkages between the mechanism of action of secreted toxins and colorectal cancer are 
shown. (C) Genotoxin colibactin secreted by Escherichia coli harboring the PKS island 
damages DNA. DNA damage by colibactin can be direct and/or through as yet unidentified 
colonic epithelial and/or other mechanisms. (D) Steps supported by experimental data 
regarding the action of BFT secreted by ETBF. See text for details.  
DC: Dendritic cell; ETBF: Enterotoxigenic Bacteroides fragilis; Mf: Macrophage; MDSC: 
Myeloid-derived suppressor cell; NOS: Nitric oxide synthase; PMN: Polymorphonuclear cell; 










































Chapter 2  
Microbiota organization rather than composition 


































The data presented in this chapter has been published in: Dejea CM, Wick EC, 
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Sporadic colorectal cancer (CRC) results from accumulated DNA mutations in colonic 
epithelial cells. Environmental factors clearly affect CRC incidence but the mechanisms 
through which these factors function are unknown. One prime candidate is an altered 
colonic microbiota. Here we show that the mucosal microbiota organization is a critical 
factor associated with oncogenic progression in a subset of CRC. We identified invasive 
polymicrobial bacterial biofilms, structures previously associated with nonmalignant 
intestinal pathology, nearly universally (89%) on right-sided tumors (13/15 CRCs, 4/4 
adenomas) but on only 12% of left-sided tumors (2/15 CRCs, 0/2 adenomas). Surprisingly, 
patients with biofilm-positive tumors, whether cancers or adenomas, all had biofilms on 
their tumor-free mucosa far distant from their tumors. Bacterial biofilms were associated 
with diminished colonic epithelial cell E-cadherin and enhanced epithelial cell IL-6 and Stat3 
activation as well as increased crypt epithelial cell proliferation in normal colon mucosa. 
High throughput sequencing revealed no consistent bacterial genus associated with tumors, 
regardless of biofilm status. However, Unifrac distance analysis revealed that biofilm 
communities on paired normal mucosa, distant from the tumor itself, cluster with tumor 
microbiomes as opposed to biofilm negative normal mucosa bacterial communities. Colon 
mucosal biofilm detection may predict increased risk for development of sporadic CRC.   
2.2 Introduction  
When healthy, the colon is covered by a mucus layer that segregates the microbiota from 
direct contact with the host colonic epithelium [13].  Breaches of this protective mucus layer 
with resulting increased contact between mucosal microbiota and the colonic epithelial cells 
have been proposed as a critical first step in inciting changes in tissue biology and/or 
inflammation that yield inflammatory bowel disease [127,128].  Concomitant with increased 
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access to the mucosal epithelium, microbial community communication (such as quorum 
sensing) is predicted to change, thereby modifying microbial structure and function and 
often resulting in biofilm formation [129]. Biofilms are defined as aggregations of microbial 
communities encased in a polymeric matrix that adhere to either biological or non-biological 
surfaces. Biofilms that invade the colonic mucus layer and come into direct contact with 
mucosal epithelial cells indicate a pathologic state [130,131]. Biofilms characterize numerous 
chronic mucosal disease states in and outside of the colon (including inflammatory bowel 
diseases, cystic fibrosis, pharyngo-tonsillitis, otitis media, rhinosinusitis, urethritis and 
vaginitis) where direct bacterial contact with epithelial cells results in perturbed epithelial 
function and chronic inflammation [132]. However, no association of biofilms with CRC 
pathologic states has been reported. 
2.3 Results 
We systematically studied the microbial communities associated with surgically-resected 
colorectal tumors (CRC and adenomas) compared with paired pathologically tumor-free 
mucosa (here-in referred to as “normal”) obtained from patients at Johns Hopkins Hospital, 
Baltimore, MD (JHH; Table S2.1) and the University of Malaya Medical Centre, Kuala 
Lumpur, Malaysia (UMMC; Table S2.2).  The normal colon tissues were obtained from the 
margins of the resected specimens furthest from the site of the tumor (Figure S2.1). In 
addition, we studied colon biopsies obtained from healthy individuals without colorectal 
tumors and without a diagnosis of inflammatory colonic disease undergoing routine 
screening colonoscopy at JHH (Table S2.3).  
Using samples from JHH, we first compared the spatial relationship of the microbiota with 
the host mucus layer and colonic epithelium using fluorescent in situ hybridization (FISH).  
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Carnoy’s solution-fixed, paraffin-embedded tissues, known to preserve the mucus layer, were 
used whenever possible. To detect all bacterial populations, we hybridized the tissues with a 
probe (Eub338) targeting the conserved 16S ribosomal RNA bacterial domain [16]. Bacterial 
biofilms were defined as massive bacterial invasions (>109 bacteria/ml) of the mucus layer 
spanning at least a linear distance of 200 µm of the epithelial surface. Bacterial biofilms were 
identified by FISH analysis on 50% (15/30) and 67% (4/6) of all evaluated CRCs and 
adenomas, respectively (Figure 2.1A, Figure S2.2).  Bacterial biofilm presence on tumors was 
ordered by geographical location along the colonic axis.  Unexpectedly, when tumors were 
ordered by geographic location along the colonic axis, tumors in the ascending colon and 
hepatic flexure were biofilm-positive in 87% (13/15) and 100% (4/4) of CRCs and 
adenomas, respectively, whereas tumors located in the transverse and descending colon 
displayed biofilms in 13% (2/15) and 0% (0/2) of CRCs and adenomas, respectively 
(P=0.0001 for carcinomas and P=0.067 for adenomas, Fisher’s exact test, Figure 2.1C). 
Surgical resection samples from the UMMC confirmed this geographical ordering of 
bacterial biofilm presence on tumors. Namely, in this Malaysian population, all four tumors 
harvested from the ascending colon and hepatic flexure were biofilm positive whereas 22% 
of tumors (4/17 CRCs and 0/1 adenoma) from the transverse and descending colon were 
biofilm positive (Table S2.2). Biofilm presence was not associated with age, gender, race, 
CRC stage, tumor size, bowel preparation or histopathologic classification.  
All biofilm-covered CRCs and adenomas exhibited the remarkable feature of bacterial 
invasion into the tumor mass (Figure 2.2A, Figure S2.3A,B, white arrows) not detected in 
biofilm-negative tumors. Scanning electron microscopy (SEM) of a tumor sample subset was 
consistent with the FISH results, revealing both direct bacterial:epithelial surface contact and 
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a dense biofilm comprised of mixed bacterial morphologies on all ascending colon tumors 
with few mucosal bacteria detected on tumors distal to the hepatic flexure (Figure 2.1D).  
These data further confirm that a breach of the colonic protective mucus layer is strikingly 
dictated by colon geographic location.  
To determine if biofilm formation was specific for the tumor microenvironment, we next 
used FISH to examine the paired normal colon tissues obtained from the surgical resection 
margin furthest from the tumor mass (Figure S2.1). No biofilms were detected on the paired 
normal surgically-resected colon tissues from patients with biofilm-negative tumors 
(adenomas or CRCs). In striking contrast, all but one normal colon tissue sample from 
patients with biofilm-covered tumors were biofilm positive. This was true for patients with 
both adenomas and carcinomas, regardless of their location within the colon. Of note, the 
single surgically-resected normal tissue on which we failed to detect a biofilm was fixed in 
formalin rather than Carnoy’s and thus not optimized for mucus preservation [133]. While 
biofilm bacterial density did not differ between tumors (CRCs or adenomas) and their paired 
normal colon tissues, biofilm depth was significantly increased on tumor samples when 
compared to their paired normal colon tissues (P=0.001 for CRCs, P=0.028 for adenomas; 
Figure 2.1B). These findings demonstrate that biofilm formation represents a broad regional 
alteration in host epithelial:microbiota association not restricted to tumor tissue. 
Screening colonoscopy biopsies from healthy individuals were typically covered with a 
mucus layer devoid of bacteria (Figure 2.1A, Figure S2.2).  A subset of colonoscopy biopsies 
(15/120, 13%) revealed thin bacterial biofilms with an average density of 108 bacteria/ml 
(Figure 2.1B). Biofilm formation on colonoscopy biopsy tissues did not differ by colon 
location (8/60, right colon vs. 7/60, left colon) (Figure S2.1B). Thus, the right colon does 
 30 
not have a greater likelihood of bacterial biofilm development in a cancer-free host. These 
findings in the healthy host are consistent with past reports detecting biofilms on ~15% of 
biopsies from asymptomatic individuals[134].  
We next evaluated the composition and spatial organization of specific bacteria within the 
biofilms using fluorescence spectral imaging employing eleven group- and species-specific 
FISH probes to target the majority (85%) of the major groups of bacteria identified by 
sequencing. Combinations of nine probes were selected for simultaneous hybridization to 
the tissues (Table S2.4). Sixteen biofilm-covered tumors (three adenomas from two patients, 
13 CRCs) and their paired normal mucosa were available for analysis along with normal 
mucosa from five right and four left colonoscopy biopsies (in three cases, biopsies were 
available from both the right and left colon).  All biofilms, whether associated with normal 
colon mucosa or tumor tissue, were polymicrobial (Figure 2.2A-C). Predominant bacterial 
phyla associated with adenomas and CRCs were Bacteroidetes and Firmicutes (family 
Lachnospiraceae including Clostridium, Ruminococcus, and Butyrivibrio). A subset of tumors 
harbored predominant populations of Fusobacteria (4/16) or Gammaproteobacteria (1/16) 
(determined to be the Enterobacteriaceae family) (Figure S2.3). Using this multi-probe method, 
the tumor-invading bacterial groups present in all CRC and adenoma tissues were also 
identified in the biofilm bacterial composition on the tumor surface consistent with tissue 
invasion by a subset of these bacterial groups (Figure 2.2A, Figure S2.3A,B). Biofilms 
identified on surgically-resected, normal tissues were also consistently diverse, comprised of 
Bacteroidetes, Lachnospiraceae, and Gammaproteobacteria (Figure 2.2B). Biofilms detected on 
normal mucosa obtained at colonoscopy from patients without CRC were similarly 
composed of Bacteroidetes and Lachnospiraceae (Figure 2.2C). A subset of biofilm-positive 
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surgically-resected normal mucosa from patients with tumors (4/16, 3 tissues from CRC 
patients and one from an adenoma patient) also revealed bacterial invasion into the colonic 
epithelial cells or submucosa (Figure 2.2D and Figure S2.4).  No mucosal biopsies with or 
without biofilms from healthy individuals revealed invasive bacteria.   
To further evaluate the colonic microbiota associated with these samples, high-throughput 
454 pyrosequencing targeting the hypervariable V3-V5 region of the 16S ribosomal RNA 
gene was performed on DNA extracted from the mucosa of 23 CRCs, two adenomas and 
their paired surgically-resected normal tissues and 22 biopsies obtained on colonoscopy of 
healthy control patients (11 right and left-matched pairs, none biofilm positive).  
Sequence analysis revealed substantial overlap between tumors (adenomas or CRCs) and 
paired normal tissue bacterial membership at the genus level; tumor bacterial membership 
was a complete subset of their normal pair in 52% of tumor:normal sets. Among the 25 
tumor:normal paired tissue samples, eight CRCs (32%, 4 right and 4 left), but not their 
paired surgically-resected normal tissues, were Fusobacteria dominant (>25% of total 
sequences) (Figure 2.2E and Figure S2.5), a finding compatible with recent reports 
[23,108,109,135]. No biopsies from healthy controls displayed dominant membership of 
Fusobacteria (Figure 2.2E and Figure S2.5). Collectively, our data are consistent with the 
concept of ‘on tumor:off tumor’ communities as previously reported[136]. 
We detected nine differentially abundant genus level groups in colonoscopy biopsies 
compared to paired normal biofilm-positive tissue samples from tumor patients (FDR<3%) 
including significant enrichment of Lactococcus, Leuconostoc, and Comamonas and other 
Burkholderiales members in colonoscopy biopsies, and, conversely, a 10-fold relative increase 
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of a candidate Ruminococcaceae member in surgically-resected paired normal biofilm-positive 
tissue samples. In contrast, we detected significant depletion of Bacilli and some Bacteroidetes 
members in surgically-resected normal biofilm-positive tissue samples with on average 28- 
and 7-fold lower relative abundance than surgically-resected normal biofilm-negative 
samples, respectively (FDR<5%) (data not shown).  
The differences between tissues with and without a biofilm from the tumor host were 
highlighted by unweighted Unifrac distance analysis and principal coordinate analysis 
(PCoA), which revealed a striking progression of bacterial dysbiosis in biofilm positive 
relative to biofilm negative mucosa, despite the minimal differentially abundant taxa between 
the two groups (Figure 2.2E,F; Figure S2.6). These analyses revealed discrete clustering of 
normal colonoscopy biopsies relative to tumor-associated communities (Figure 2.2F, Figure 
S2.6); microbial populations from these two sample types were the most structurally 
divergent (P<8e-7). Communities from CRC-associated normal mucosa without biofilm 
were on average significantly closer in overall structure to healthy colonoscopy biopsy 
populations than to CRC-associated communities (P=0.001). In striking contrast, biofilm-
positive normal tissue communities were significantly closer in structure to CRC-associated 
populations than to those of biopsies from healthy individuals (P=1e-8). This distinction 
supports the notion that biofilm presence correlates with the dysbiosis detected within the 
tumor-associated microbiota. Our findings suggest that stepwise colon mucosal microbial 
community dysbiosis, largely with depletion of common microbiota community members, 
parallels the transition from normal colon mucosa to CRC. 
Can biofilms modify epithelial biology before initiation of transformation? To evaluate this 
conjecture, we conducted analyses to evaluate colonic epithelial cell biologic changes relevant 
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to carcinogenesis including barrier permeability (using E-cadherin detection as a marker) 
[137,138], IL-6 levels, Stat3 activation [139,140], proliferation and apoptosis in normal 
tissues from CRC patients as well as from healthy individuals. Loss of E-cadherin activates 
Wnt signaling in colon cancer and IL-6-driven Stat3 activation in colonic epithelial cells is 
critical to colon carcinogenesis in multiple murine models. These analyses showed marked 
differences between biofilm positive and biofilm negative normal colon tissues from the 
CRC host. Namely, biofilm positive normal tissues in the CRC host displayed significantly 
reduced crypt cell E-cadherin (Figure 2.3A,C) with significantly increased epithelial cell IL-6 
(Figure 2.3A,D,E and Figure S2.7). Consistent with the IL-6 colonic epithelial cell 
localization, Stat3 activation (measured by pStat3 immunohistochemistry) was significantly 
increased in the epithelial cells (Figure 2.3A,F). Consistent with the action of Stat3 to 
promote epithelial cell proliferation and survival[139], we further detected a significant 
increase in crypt epithelial cell proliferation, as measured by Ki67 staining, in normal tissues 
covered with biofilms from CRC patients compared to normal tissues without a biofilm, also 
from CRC patients (P<0.0001, Figure 2.4A). In contrast, biofilm negative normal colon 
tissues from the CRC host displayed intact E-cadherin (Figure 2.3A,C and Figure S2.9). 
Lamina propria IL-6 and Stat3 activation did not differ between biofilm positive and 
negative normal colon tissues, both from the CRC host (Figure 2.3A, Figures S2.8, S2.10A).  
Notably, although epithelial cell E-cadherin was quantitatively unchanged (Figure 2.3B, 
Figure S2.11A,B) in biofilm positive vs. biofilm negative colonoscopy biopsies from healthy 
subjects without CRC, E-cadherin localized to the basal pole of the epithelial cells in biofilm 
positive colonoscopy biopsies from healthy subjects without CRC (Figure 2.3B, insets). IL-6 
detection was also significantly increased in biofilm positive colonoscopy biopsies from 
healthy subjects without CRC (Figure 2.3B, Figure S2.11C) whereas Stat3 activation was 
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similar in biofilm positive and negative colonoscopy biopsies from healthy subjects (Figure 
2.3B, Figure S2.10B). Nonetheless, epithelial cell proliferation was significantly increased in 
biofilm positive colonoscopy biopsies from healthy individuals (P<0.01, Figure 2.4B).  In 
parallel, TUNEL staining was performed to determine if increased proliferation was simply a 
byproduct of increased cell turnover (Figure S2.12). Importantly, epithelial cell apoptosis was 
not increased in biofilm positive tissues suggesting that the increased epithelial proliferation 
measured is a pro-oncogenic state. This contrasts with the biofilm negative normal tissues 
from the CRC host where lower proliferation (Figure 2.4A) was associated with significantly 
increased apoptosis (Figure S2.12). Spearman correlations between Ki67 staining and genus-
level relative abundances were sought in samples stratified by biofilm positive and negative 
status. No bacterial genera significantly correlated with the Ki67 counts in any subgroup.  
2.4 Discussion 
While it has been long suspected that bacteria contribute to chronic inflammation leading to 
CRC, this is the first time that bacterial biofilms, a known driver of tissue inflammation 
[128], have been identified in CRC. Further our data show biofilm formation in both the 
colon cancer host and healthy subjects is associated with reduced or redistributed colonic 
epithelial cell E-cadherin consistent with increased epithelial permeability. Our detection of 
enhanced IL-6 associated with biofilm formation even in healthy subjects without CRC 
suggests that early biofilm formation can initiate pro-carcinogenic tissue inflammation; in the 
cancer host with biofilm formation, IL-6 is notably localized in colonic epithelial cells with 
Stat3 activation. The IL-6 family of proinflammatory cytokines and their downstream 
effector Stat3 have been shown to promote CRC through increased epithelial proliferation, 
diminished apoptosis and/or angiogenesis [139,140]. Thus, our data support a model 
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whereby biofilm formation enhances epithelial permeability that increases direct access of 
bacterial antigens/mutagens to an unshielded epithelial surface and promotes pro-
carcinogenic tissue inflammation. Collectively these events are predicted to induce epithelial 
cell mutations with consequent increased proliferation of colonic epithelial cells. In this 
regard, a key observation linking biofilm formation to tumor biology is our identification of 
the tight association between mucosal biofilm formation and the pro-cancerous state of 
increased epithelial proliferation.  Individual genetic polymorphisms likely govern the 
composition of the mucosal immune response to the mucosal biofilms with Th17-dominant 
mucosal immune responses increasingly associated with oncogenesis and poor outcomes in 
CRC [70,141].   
It has been hypothesized that differences in diet have significant effects on the gut 
microbiome and, thus, whether diet relates to biofilm status is an interesting question. 
Definitive diet-microbiome correlations require large epidemiologic studies that are difficult 
to control. We do note that the primary associations between biofilms on tumor and 
associated normal mucosa predominantly in right-sided colon cancers are faithfully 
reproduced in a population of CRC patients from Malaysia, who, in general, have a very 
different diet and environmental exposures than patients from the US. That biofilm patterns 
in colon cancer are so similar in such different populations, despite likely differences in 
microbiota, emphasizes the importance of microbiota structure. 
The primary findings of this study are that the vast majority of right-sided CRCs are 
associated with a dense bacterial biofilm and that the normal colonic mucosa from patients 
whose tumors are covered with biofilms (whether right- or left-sided) are biofilm positive.  
None of the normal mucosa from patients with biofilm-negative CRCs possessed a biofilm.  
These findings introduce the concept that the organization, as opposed to the species 
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composition per se, of the mucosa-associated microbial community is an important factor in 
CRC pathogenesis, particularly in the proximal colon. Microsatellite instability, 
hypermethylation, hypermutation (not all correlating with the presence of microsatellite 
instability) and the BRAF(V600E) mutation have also been associated with right colon 
cancer[65].  
Based on the numbers of patients and normal individuals with colonic biofilms, we speculate 
that colorectal cancers develop in two different settings:  individuals with biofilms and 
individuals without them.  Based on the data described here, the risk of developing CRC is 
more than 5-fold higher in the patients with biofilms compared to those without biofilms.  
This risk is considerably higher than that reported for other environmental associations with 
CRCs [142,143]. One can envision minimally invasive assays to evaluate the presence of 
these biofilms as well as probiotic treatments that could eliminate them.  Based on these 
findings, prospective epidemiologic studies to directly test these hypotheses are currently 
being designed. 
 
2.5 Materials and Methods 
Ethics Statement 
This study was approved by the Johns Hopkins Institutional Review Board and the Medical 
Institutional Review Board and UMMC Medical Ethics Committee at the University of 
Malaya. All samples were obtained in accordance with the Health Insurance Portability and 
Accountability Act (HIPAA). 
Patient Selection and Sample Acquisition  
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Colon tumors (adenomas and cancers) and paired normal tissues were collected from 
patients undergoing surgery at Johns Hopkins Hospital or the University of Malaya Medical 
Centre in Kuala Lumpur, Malaysia. All tissue not needed for pathologic diagnosis was rapidly 
preserved in formalin, Carnoy’s solution and/or RNAlater (Qiagen Inc., Germantown, MD) 
for analysis. Patients who received pre-operative radiation and/or chemotherapy or with a 
personal history of CRC were excluded. For patients in this study, two mechanical bowel 
preparations were routinely used and recorded (polyethylene glycol [MiralaxTM or FortransTM] 
or Fleet Phospho-sodaTM enema [PE]). The proportion of individuals who received 
polyethylene glycol (PEG) vs. PE use prior to surgery was identical in the biofilm positive 
and negative groups.  Pre-operative intravenous antibiotics were administered in all cases 
(cefotetan, clindamycin/gentamicin or cefoperazone/metronidazole). No patient received 
pre-operative oral antibiotics. Dietary information was not available. 
Healthy control patients undergoing screening colonoscopy or colonoscopy for diagnostic 
work-up (eg, anemia) at Johns Hopkins Hospital were enrolled. All patients underwent a 
standard mechanical bowel preparation. Mucosal biopsies from grossly normal colon were 
taken from the right (cecum or ascending) and left (descending or sigmoid) colon during the 
colonoscopy. All tissue was rapidly preserved in formalin, Carnoy’s solution and/or 
RNAlater for analysis. Patients who had a personal history of CRC, inflammatory bowel 
disease or were treated with antibiotics within the past three months were excluded.  
Fluorescent in situ hybridization (FISH) 
Fixed, paraffin-embedded tissues were sectioned to 5 µm thickness and de-waxed following 
standard procedures.  Sections were stained with Periodic acid Schiff (PAS) to confirm 
mucus presence and preservation and successive sections were hybridized with the Eub338 
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universal bacterial probe and with a nonsense probe to test for nonspecific binding of 
probes. Slides were imaged using a Nikon E800 microscope with NIS elements software or 
Zeiss LSM 510 META laser scanning microscope with LSM imaging software (for confocal 
imaging). Paired images are presented at identical exposure intensities.  
Oligonucleotide probes were synthesized and conjugated at the 5’ end to the fluorophores 
listed in Table S2.4 (Life Technologies).  Probes were applied to slides at a concentration of 
2 pmol/μl of each probe in prewarmed hybridization buffer (900 mM NaCl, 20 mM Tris pH 
7.5, 0.01% SDS, 20% formamide). Slides were incubated at 46°C in a humid chamber for 2 
hours, and washed at 48°C for 15 minutes in wash buffer (215 mM NaCl, 20 mM Tris pH 
7.5, 5 mM EDTA).  Slides were dipped in water, then in 100% ethanol, air-dried, and 
coverslips were mounted using ProLongGold antifade reagent (Life Technologies).      
Biofilm Bacterial Quantification 
Biofilm bacterial density and depth were measured using slides hybridized with the universal 
bacterial probe, Eub338, and imaged at 1000x magnification with a Nikon E800 microscope 
and Nikon NIS elements viewing software.  
Measures of bacterial density were based on the following model. A 10x10 µm square placed 
over a region of a 5 µm thick tissue section (500 µm3) constitutes a volume of 5x10-10 ml. 
One bacterium in this volume is equivalent to 2 x 109 bacteria/ml.  The visual distinction of 
a single bacterium is lost but spaces can still be seen between the bacteria when 250 bacteria 
occupy a 10x10 µm space; these cases were assigned a concentration of 1011 bacteria/ml.  A 
solid mat of bacteria with no discernible spaces between the bacteria constitutes an increase 
to 2500 bacteria in a 10x10 µm space; these cases were assigned a concentration of 1012 
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bacteria/ml [144]. The mean of five (10x10 µm) fields was used to determine bacterial 
density.  
The biofilm depth was measured using ImageJ software calibrated with an image of a stage 
micrometer from the same microscope and magnification used in the images being 
quantified.  Biofilm depth was calculated as the mean of five measurements taken along a 
200 µm span of the biofilm.  
Scanning Electron Microscopy (SEM)   
Tissue samples were fixed in 2% glutaraldehyde, 2% paraformaldehyde in 0.1 M sodium 
cacodylate (NaCaco), 3 mM CaCl, 1% sucrose pH 7.4 overnight with gentle rocking. 
Samples were rinsed three times in washing buffer (0.1 M NaCaco, 3 mM CaCl, 3% sucrose), 
and placed in 1% osmium tetroxide in 1 M NaCaco for 1 hour in the dark.  Samples were 
rinsed twice in distilled water followed by dehydration in an ethanol series. Samples were 
next placed in a 1:1 mixture of 100% ethanol to hexamethyldisilazane (HMDS) for two 
washes of 10 minutes each. This was followed by three washes with 100% HMDS for five 
minutes each. Samples were then removed and placed in a vacuum desiccant overnight 
followed by gold palladium coating before viewing under a Leo Zeiss Field emission SEM. 
Samples were scored by two independent observers for biofilm presence and morphologies. 
Fluorescence Spectral Imaging and Unmixing  
Samples that were determined to have a bacterial presence by universal probe were next 
analyzed by fluorescence spectral imaging as described above (see Fluorescent in situ 
hybridization Methods) using 9 probes simultaneously, targeting broad phylogenetic groups 
and subgroups (Table S2.4) [145-155] .    
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Spectral images were acquired with a Zeiss LSM 780 laser scanning confocal microscope 
with a 32-channel GaAsP detector and Zeiss ZEN software. All images were acquired with a 
Zeiss Plan-Apochromat 40x/1.4 NA(420762-9900) objective; 2x line averaging, 2048x2048 
pixel frame size, 1.58 μs pixel dwell time; and 8.7 nm spectral resolution.  Five fields of view 
were selected per sample.  Spectral images of each field of view were acquired sequentially 
with six different lasers proceeding from long to short excitation wavelength: HeNe633 
(633nm), HeNe594 (594nm), DPSS561-10 (561nm), Ar514 (514nm), Ar488 (488nm), and 
Diode 405-30 (405nm). 
FISH probe reference spectra were measured from spectral images of pure populations of 
cultured bacterial cells singly labeled with the appropriate taxon-specific FISH probe.  Tissue 
autofluorescence reference spectra were measured from spectral images of tissue subjected 
to the FISH procedure but without probe, and imaged under experimental imaging 
conditions. 
Linear unmixing was performed with a custom Mathematica script using a least squares 
method.  Each spectral image was unmixed independently using the appropriate reference 
spectra for the excitation wavelength.  For each field of view, unmixed channels for each 
FISH probe were extracted from the unmixing results corresponding to the appropriate 
excitation wavelength.  Extracted unmixed channels were compiled and colorized in ImageJ 
using the Image5D plugin. 
Sample Preparation for Sequencing 
Mucosal samples from surgically-removed tumors, paired surgical normal tissues and 
colonoscopy biopsies were collected in the pathology or endoscopy suites at Johns Hopkins 
Hospital and immediately placed in RNAlater (Qiagen Inc. Germantown, MD) and stored at 
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-80oC.  Tissue samples (100-500 mg) were placed in a 15 ml conical tube with 2.5 ml Qiagen 
buffer ASL. Samples were incubated at 95oC for 15 minutes with frequent vortexing to 
remove bacteria from the epithelial surface. Following the dislodging of mucosal associated 
bacteria, 1.4 ml of supernatant was removed and cells were thoroughly lysed using a 
Barocycler NEP2320 (Pressure Biosciences, Inc. South Easton, MA), by cycling between 
atmospheric pressure, 0 psi to 25,000 psi while maintaining a temperature of 60oC.  
Following pressure lysis, DNA was extracted using the QIAamp DNA Stool Kit (Qiagen). 
Recovered genomic DNAs were quantitated using a Nanodrop spectrophotometer (Bio-Rad 
Life Science Research, Hercules, CA). The V3-V5 region of bacterial 16S rDNA was 
amplified and sequenced following the procedures described by the Human Microbiome 
Project standard protocol (http://www.hmpdacc.org/doc/16S_Sequencing_SOP_4.2.2.pdf). 
Briefly, the V3-V5 region of 16S rDNA was amplified with PCR primers (357F 5’ 
CCTACGGGAGGCAGCAG 3’ and 926R 5’ CCGTCAATTCMTTTRAGT 3’) that were 
appended with Roche 454 Titanium FLX library adapter sequences. All B-adapter primers 
were identical, while A-adapter primers also contained a unique barcode of 5-10 nucleotides 
to allow indexing of individual samples. Each sample was PCR amplified for 30 cycles with 
Phusion HF DNA polymerase (New England Biolabs Inc. Ipswich, MA). PCR products 
were purified by gel electrophoresis. Bands of the appropriate size were excised from the gel 
and purified using the QIAquick Gel Extraction Kit (Qiagen Inc. Germantown, MD). 
Purified DNAs were quantified using the 454 FLX Library Quantification Kit (KAPA 
Biosystems Inc. Woburn, MA) and pooled for sequencing in equal molar quantity.  
Sequence data analysis 
Raw sequence reads were initially assigned to samples based on multiplex identifier barcodes, 
trimmed of forward and reverse primer sequences, and filtered for quality and length 
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(minimum 150 bp) using the QIIME package (v1.6.0) [156-159] . High quality reads were 
then organized by sample and error-corrected using the Acacia tool (v1.52) [160] , and 
subsequently screened for chimeras utilizing de novo UCHIME (v4.2.40) [161] . Chloroplast 
DNA was identified and removed using the RDP Bayesian classifier (v2.5) [162] . 
The final high-quality contaminant-free dataset was then submitted to the CloVR-16S 
pipeline (v1.1)[163]for diversity estimation, taxonomic characterization and comparative 
analysis of sample groups of interest. Sequences were clustered de novo into species-level 
operational taxonomic units (OTU) using UCLUST[164] with a 95% identity 
threshold[125,165], Taxonomic assignment of OTU representatives was performed using the 
RDP classifier with a minimum threshold of 0.5. There was no exclusion removal of low 
frequency OTUs (e.g., singletons). Pipeline runs were executed using CloVR (v2012.11.16) 
on the DIAG academic cloud (http://diagcomputing.org).  
Immunohistochemistry and Immunofluorescence 
Immunohistochemistry was performed on tissue fixed in 10% formalin and paraffin-
embedded following standard procedures.  Sections were de-paraffinized and rehydrated 
through a xylene, ethanol-water gradient.  Ki67 staining was performed on an automated 
Benchmark ST Staining System using detection reagents from the iView DAB detection kit 
(Roche) with Ki67 monoclonal antibody (clone 30-9, Roche). Antibody for phospho-Stat3 
(clone Tyr705 D3A7, Cell Signaling Technology) was applied at 1:400 dilution overnight 
following antigen retrieval. The TUNEL assay was performed per the manufacturer’s 
instructions using the fluorescein in situ cell death detection kit (Roche). Immunofluorescent 
staining was performed following standard procedures. Antibodies for Il-6 (ab6672, Abcam), 
E-cadherin (Mouse IgG2a, BD), and smooth muscle antigen (SMA) (clone 1A4, mouse 
monoclonal, Sigma) were used at 1:400, 1:100, 1:500 dilutions respectively.  Enzymatic 
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antigen retrieval was performed prior to IL-6 antibody application (15 minutes proteinase K 
treatment at 37°C); citrate-based antigen retrieval was performed prior to E-cadherin and 
SMA (microwave boiling in antigen unmasking solution; Vector Laboratories).  All 
antibodies were applied overnight at 4°C, followed by secondary antibody application for 
one hour at room temperature.  All slides were treated with DAPI for 10 minutes and 
mounted with glass coverslips using Prolong Gold antifade reagent (Life Technologies).             
Quantification of Stat3, Proliferation and Apoptosis 
Phosphorylated Stat3 (pStat3) was semi-quantitatively assessed using a 0-+3 grading scale in 
which epithelial cell and immune cell pStat3 are individually assessed [166]. 
A total of 5 well-oriented crypts were selected from each sample to be scored for Ki67+ 
cells by two blinded individuals.  Positive cells were counted on both sides of each crypt 
starting at the base and ending at the luminal surface in increments of 15 cells. Each interval 
was scored as cells positive per 15 cells. The mean number of proliferating cells within each 
interval was calculated for each analyzed sample, groups were compared using the 
nonparametric Mann Whitney U test. 
Apoptosis scoring was performed by two independent observers. TUNEL positive cells 
were counted per 1000 epithelial cells in 10 randomly selected fields. Results were graphed as 
percent positive and groups were compared using the nonparametric Mann Whitney U test.    
Immunofluorescence quantification of IL-6 and E cadherin 
Pixel intensity per area was measured from selected cell populations (differentiated surface 
epithelium, crypt epithelium, lamina propria or whole tissue) and background fluorescence 
was subtracted using imageJ. For differentiated surface epithelial quantification, five 
measurements were taken from 400x images along 100μm linear distance of surface 
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epithelium (for a total of 500 linear μm measured per sample).  Crypt epithelial 
measurements were collected from the base of five crypts. Total lamina propria fluorescence 
was quantified in three distinct, representative 400x fields per specimen.  Total tissue 
fluorescence was measured as total fluorescence intensity upon selection of the entire tissue 
specimen at 200x on at least two tissue sections per specimen. Individual specimen 
fluorescence intensity values were calculated as the mean of the individual measurements 
made for each specimen.  
Isolation of colonic epithelial cells 
Colonic epithelial cells were isolated using a modified rapid low-temperature method[167]. 
Briefly, approximately 500 mg of epithelial tissue was washed with ice-cold PBS and divided 
into 2-3 mm fragments before transferring to chelating buffer (27 mM trisodium citrate, 
5mM Na2PO4, 8mM KH2PO4, 1.5mM KCl, 0.5 mM DTT, 55mM D-sorbitol, 44 mM 
sucrose, 6mM EDTA, 5mM EGTA, pH 7.3) for 45 minutes at 4°C.  Cells were dissociated 
by repeated vigorous shaking. After removal of debris, using a 100 μm cell strainer, epithelial 
cells were collected by centrifugation at 150 g for 10 minutes and stored at -80°C until 
protein extraction. 
IL-6 ELISA  
Colonic epithelial cell pellets were lysed in cell extraction buffer (Life Technologies) for 30 
minutes on ice with vortexing at 10 minute intervals.  Cellular debris was removed by 
centrifugation at 13,000 rpm for 10 minutes. One microgram of total protein from the clear 
lysate was used in the IL-6 ELISA (Sigma) according to the vendor’s protocol. 
Statistical analysis 
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Prior to downstream statistical analysis, sequence data were subsampled to equivalent depths 
(2500 sequences per sample) [158,168] . Unweighted UniFrac distances [169], and principal 
coordinate analysis plots were computed in QIIME. Additional statistical analyses were 
performed in R (v2.15.1) and included paired Student’s t test, Fisher’s exact test and the 
nonparametric Mann Whitney U test as appropriate. Pairwise beta-diversity comparisons 
















Figure 2.1 Detection and quantification of bacterial biofilms on colon tumors. (A) FISH of 
all bacteria (red) on cancers (top panels), paired normal tissue from patients with CRC 
(middle panels) and colonoscopy biopsies from healthy individuals without CRC (bottom 
panels). All were counterstained with the nuclear stain, DAPI (blue). The top white brackets 
demarcate the mucus layer and the bottom white brackets denote the cytoplasm separating 
the nucleus (blue) of the colorectal epithelium from the mucus layer. PAS stains (Figure S2) 
further delineate the mucus layer on these samples. Insets depict 100X closeup showing 
close contact between bacteria and epithelial cells in Patient A.  The pale, non-punctate red 
staining of the mucus layer in patients without biofilms (Patient B) represents non-specific 
binding to the mucus layer, which is easily demarcated from the bright red punctate staining 
of the bacteria infiltrating the mucus layer in patients with biofilms. Scale bar 50 µm. (B) 
Biofilm depth and density measurements from right CRCs/surgical normal pairs (n=15), 
right adenomas/surgical normal pairs (n=4), left CRCs/surgical normal pairs (n=15), left 
adenomas/surgical normal pairs (n=2), and right/left paired normal colonoscopy biopsies 
from healthy individuals without CRC (n=60). Data displayed as bar and whisker graphs 
where line designates the median, boxes the 25/75th percentile and whiskers the 95th 
percentile. (C) Geographical distribution of tumors (CRC, n=30 and adenomas, n=6) with 
biofilm designation. (D) SEM images. Left. Biofilm on a right colon cancer dominated by 
filamentous bacteria .  Middle. Biofilm-negative left colon cancer where no bacteria are 
visualized. Right. Image of bacterial contact with host epithelium (white arrow) on biofilm-
covered right colon adenoma. Mixed bacterial morphology (rods and cocci, *) is seen. All 















































Figure 2.2. FISH and sequencing analysis of tissue reveal invasive polymicrobial biofilms 
and transitioning microbial populations. (A, B and C) Multiprobe spectral images of FISH-
targeted bacterial groups (40x). Bacteroidetes (green), Lachnospiraceae (magenta), Fusobacteria 
(cyan), Enterobacteriaceae (orange), B. fragilis (red) are represented within the biofilms, and 
tissue autofluorescence is white. (A) Multi-group bacterial biofilm with invasion of cancer 
tissue (white arrows). Dotted line depicts tissue border. Right cancer with Fusobacteria, 
Bacteroidetes, Lachnospiraceae, and Enterobacteriaceae. Dominant group in left cancer is 
Bacteroidetes. Cancer-invading bacteria represent a subset of biofilm community members. (B) 
Bacterial biofilms on paired normal tissue comprised of Lachnospiraceae, Bacteroidetes, and 
Enterobacteriaceae. (C) Thin biofilms detected on right (Bacteroidetes, Lachnospiraceae and 
Enterobacteriaceae) and left (Bacteroidetes and Lachnospiraceae) normal colonoscopy biopsies (D, 
left). All bacteria FISH (red) with DAPI nuclear counterstain (blue) of paired normal tissue 
covered by a biofilm (20x) from a patient with CRC. White arrows mark sites of biofilm 
infiltration of the epithelium (20x). (D, right) Confocal z-stack of tissue bacterial (red) 
invasion (40X) denoted by white box in D, left. Disordered epithelial cells and leukocytes are 
visible at the infiltrated sites, while surrounding epithelial cells are intact and ordered. (Scale 
bars: 50 µm in A, B, C and D) (E) Histogram of bacterial classes represented on biofilm 
positive and negative samples as defined by sequence analysis. Tumor denotes 23 CRCs and 
2 adenomas. (F) PCoA plot (based on unweighted UniFrac distances) displaying mucosa 
community structure of all samples (each point reflects an individual sample). Colonoscopy 
biopsies from healthy individuals without CRC (n=21, red) and paired normal tissues 
without a biofilm from patients with CRC (n=12, orange) transition to normal tissues with a 
biofilm from patients with CRC (n=13, green) that cluster more closely to biofilm positive 
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adenomas (n=2, dark blue squares) and CRCs with (n=12, dark blue) and without (n=11, 













Figure 2.3 Biofilms are associated with changes in E-cadherin, IL-6 and Stat3 activation. (A 
and B) Evaluation of E-cadherin and IL-6 by immunofluorescence (green) and activated 
Stat3 (pStat3, brown nuclei) by immunohistochemistry. Blue, nuclear DAPI counterstain; 
red, smooth muscle antigen (SMA). Scale bars are 100 μm (E-cadherin) and 50 μm (IL-6, 
pStat3). (A). Normal colonic tissues associated with a biofilm from patients with CRC (left), 
obtained during surgery, display diminished crypt colonic epithelial cell E-cadherin (white 
arrows, n=7 biofilm positive or negative tissues) and increased epithelial cell IL-6 (white 
arrows, n=13 biofilm positive or negative tissues) as well as epithelial cell pStat3 (black 
arrows, n=16 biofilm positive and n=12 biofilm negative tissues). Normal colonic tissues 
without a biofilm from patients with CRC (right), likewise obtained during surgery, display 
intact E-cadherin. IL-6 and pStat3 are detected in the lamina propria. Quantification of crypt 
cell E-cadherin (fluorescence intensity), epithelial cell IL-6 (fluorescence intensity and 
isolated colonic epithelial cells (CEC) by ELISA) and epithelial cell pStat3 
(immunohistochemistry) are shown in C-F, respectively. Data displayed as bar and whisker 
graphs where line designates the median, boxes the 25/75th percentile and whiskers the 95th 
percentile (C,D) or mean+/-SD (E,F). See Supplemental Methods for details. (B). Biofilm 
positive colonoscopy biopsies from subjects without CRC (left) display epithelial cell  E-
cadherin redistribution (inset) and increased tissue IL-6 while biofilm negative colonoscopy 
biopsies (right) display intact E-cadherin and modest lamina propria IL-6 expression. pStat3 
is observed in the lamina propria immune cells in both biofilm positive and biofilm negative 
colonoscopy biopsies. See Supplemental Figures 3.10 and 3.11 for E-cadherin, IL-6 and 








































Figure 2.4 Scoring of Ki67 positive cells from the base of the crypt to the luminal surface.  
Normal tissues from patients with CRC obtained at surgery (A) with (n=17) and without 
(n=18) a biofilm as well as normal mucosa from healthy subjects obtained via colonoscopy 
(B) with (n=7) and without (n=10) a biofilm displayed increased proliferation in a biofilm 
setting. Data displayed as mean +/- SEM in groups based on distance from crypt base (<15 






Figure S2.1. Example of mucosal tumor and normal tissue sites selected for analyses of 




Figure S2.2. PAS-stained histopathology images of cancer and normal tissue pairs from 
Patient A and Patient B as well as the right and left normal colonoscopy biopsies from 
healthy individuals shown in Figure 1A. The mucus layer of the epithelium of each image, 





Figure S2.3. Bacterial biofilms detected on CRCs and adenomas have variable 
compositions. (A) Right adenoma biofilm comprised solely of Enterobacteriaceae (orange) and 
Lachnospiraceae (magenta). (B) Right CRC biofilm composed of Bacteroidetes (green) and 
Lachnospiraceae (magenta). (C) Right CRC biofilm composed of Fusobacteria (cyan), Bacteroidetes 
(green) and Lachnospiraceae (magenta). (Scale bar: 50 µm). Dotted white lines depict margin 
between bacterial biofilm and tumor tissue; white arrows identify bacteria invading into 









Figure S2.4.  A series of eight z-stack slices (through 4 µm) depicting bacterial invasion of 
normal tissue (epithelial cells and submucosa) from a patient with colorectal cancer (Scale 











Figure S2.5. Individual subject histograms of bacterial classes grouped by tissue type and 
biofilm status. Tumors comprised of 23 CRCs and 2 adenomas. Paired normal tissues 
indicate surgically-resected normal mucosa from tumor host. Colonoscopy biopsies indicate 












Figure S2.6. (A) Pairwise display of the first three principal coordinate axes of the PCoA. 
(B) Unweighted Unifrac distance analysis. Dark-shaded bars display all tissues from tumor 
hosts (surgical paired normal or tumor) whether biofilm positive (N=13) or negative (N=12) 
and all colonoscopy biopsies (N=21) evaluated by sequence analysis. Light-shaded bars 









Figure S2.7. Colon mucosal tissue samples showing IL-6 immunofluorescence staining and 
controls. (A) IL-6 immunofluorescence staining; (B) Parallel section treated with IgG 




















Figure S2.8. IL-6 quantification by  immunofluorescence in lamina propria from biofilm 
positive or biofilm negative normal surgical colon tissues from patients with CRC. Data 
displayed as bar and whisker graphs where line designates the median, boxes the 25/75th 















Figure S2.9. Measurement of E-cadherin in differentiated epithelial cells in biofilm positive 
and biofilm negative normal surgical tissues from patients with CRC. Data displayed as bar 
and whisker graphs where line designates the median, boxes the 25/75th percentile and 












Figure S2.10. Quantification of immunohistochemistry (IHC) for activated Stat3 (pStat3) in 
biofilm positive or biofilm negative normal colon tissues from patients with CRC (A) and 
biofilm positive and biofilm negative colonoscopy biopsies from subjects without CRC (B). 
Epithelial cell pStat3 was significantly increased in biofilm positive normal tissues from CRC 










Figure S2.11. Quantification of E-cadherin or IL-6 fluorescence intensity in biofilm positive 
and biofilm negative colonoscopy biopsies from subjects without CRC. E-cadherin 
fluorescence intensity was quantified separately in differentiated surface epithelial cells (A) 
and crypt cells (B). Total IL-6 fluorescence intensity was quantified in each biopsy specimen 
(C). Total IL-6 fluorescence was significantly higher in biofilm positive compared to biofilm 
negative biopsy specimens. Data displayed as bar and whisker graphs where line designates 
the median, boxes the 25/75th percentile and whiskers the 95th percentile. A.U., Arbitrary 






Figure S2.12. Percent of apoptotic cells scored per 1000 epithelial cells counted. Normal 
surgical tissue from patients with CRC with and without a biofilm, along with normal 
mucosa from colonoscopy biopsies from healthy individuals with and without a biofilm 





























































































































Metabolomics correlate biofilm polyamine 
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3.1 Abstract 
The human colonic microbiome has been suggested to contribute to the eitology of 
colorectal cancer (CRC). Experimental evidence supports the potential for single species to 
act independently as oncogenic agents but also for the microbial consortia and their 
collective metabolites to influence the initiation or progression of CRC.  Here we utilized 
mass spectrometry to investigate the metabolic contribution of bacterial biofilms adherent to 
the mucosal epithelium of colorectal cancer.  We evaluated both tumor and paired normal 
tissues from CRC patients, with and without a biofilm, as well as colonoscopy biopsies 
without a biofilm from healthy subjects.  An upregulation of polyamines N1, N12-
diacetylspermine, N1-acetylspermidine, N1-acetylspermine and spermidine, previously 
determined to increase cellular proliferation in vitro, were identified in tumor tissues. 
Furthermore, comparison of colon cancer and paired normal tissues with or without 
biofilms revealed significant enhancement of N1, N12-diacetylspermine in both biofilm 
positive colon cancers and their matched biofilm-positive normal tissues when compared, 
respectively, to colon cancer and paired normal tissues without biofilms.  Antibiotic 
treatment, which cleared biofilms, decreased N1, N12-diacetylspermine levels to those seen in 
biofilm negative colon cancers, suggesting that both host cancer and bacterial biofilm 
microenvironment contribute to the polyamine metabolite pool. These results demonstrate 
that colonic mucosal biofilms alter the cancer metabolome to produce a regulator of cellular 






Colon cancer develops over decades through the step-wise accumulation of genetic 
mutations [4]. Of the many environmental factors with potential to contribute to the 
initiation and progression of CRC, accumulating data suggests that the intestinal microbiome 
is playing a role[136,170]. The colon microbiota exerts the potential to mediate 
inflammation, DNA damage, and epithelial cell biology [7,8,171].  Recent findings by our 
group revealed that a subset of tumors, largely cancers from the right ascending colon, and 
paired normal mucosa are covered with an invasive polymicrobial biofilm that lines the 
epithelial surface (CHAPTER 2) [172]. Principle coordinate analysis of 454 sequencing 
reads of microbiomes revealed a progressive dysbiosis whereby biofilm-covered paired 
normal tissues clustered more closely to tumor populations than paired normal tissues 
without a biofilm. Further, these bacterial biofilms are associated with increased epithelial 
IL-6, pSTAT3 and crypt proliferation, a pathway well established with a pro-oncogenic role.   
A viscous inner gel-like mucus layer covers the epithelium of the healthy human colon [13]. 
Bacterial perturbation of the inner mucus layer, as identified on right-sided CRCs, 
constitutes a pathogenic biofilm disease-state that facilitates direct contact between the 
microbial consortia and host epithelial cells. This close proximity of mucosal associated 
bacteria likely exacerbates the metabolomic potential of these organisms. We hypothesized 
that the altered microbial structure of this biofilm might affect cancer biology by modulating 
the colon cancer metabolome, yielding metabolites that promote oncogenesis.    
  
3.3 Results  
We investigated the colon tissue metabolome of biofilm-positive and biofilm-negative CRC 
mucosa along with colonoscopy biopsies from healthy subjects without CRC (Patient 
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metadata in Tables 3.1 and 3.2).  Global changes in metabolic products between cancer and 
paired normal tissues were assessed using an untargeted metabolomics approach.  This 
analysis revealed 304 differentially regulated products, that vast majority of which were 
increased in the cancer tissues compared to the paired normal (blue circles) (Fig3.1A).  
Specifically, N1, N12-diacetylspermine was determined to be one of the most upregulated 
products with a fold increase of 9.4.  The identification of this polyamine was confirmed via 
tandem mass spectroscopy (MS) using standards (Fig3.1A, B).  Two additional metabolites 
belonging to the polyamine class, N1-acetylspermidine and N1-acetylspermine, were also 
upregulated in cancer tissue samples at 3.7 and 3.6 fold, respectively.  Further analysis of the 
mass spectra and tandem MS data revealed that a number of additional products could be 
classified as phospholipids and fatty acids, in addition to the observation of multiply charged 
ions coming from proteins.  However, this study focuses on an in-depth analysis of 
polyamines as they have been suggested to be pro-oncogenic, both in vitro and in vivo[173]  
We next stratified the untargeted metabolomics approach to explore the differential 
contribution of biofilms to the metabolomic profile.  Samples were assessed for biofilm 
presence by fluorescent in situ hybridization (FISH) using the EUB338 probe directed to the 
conserved 16S ribosomal RNA bacterial domain.  First, we directly compared colon cancer 
tissues with and without a biofilm to understand the impact of biofilm on the cancer 
metabolome (Fig 3.1C).  An additional significant increase in polyamine concentration was 
detected in the biofilm positive cancer tissues compared to biofilm negative cancer tissues. 
Once again, N1, N12-diacetylspermine displayed the highest upregulation, 3.8-fold, while N1-
acetylspermidine and N1-acetylspermine were increased 1.7 and 2.0-fold. Importantly, our 
sample set included two cancer specimens from the left descending colon that were biofilm 
positive.  These two samples had the highest concentrations of N1, N12-diacetylspermine of 
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all the cancer samples examined, confirming that this metabolite is not simply a product of 
the geographic location of the cancer in the colon but rather specifically related to the 
presence of a biofilm.  All paired normal samples maintain the same biofilm status as their 
matched tumor.  When biofilm positive paired normal samples were compared to their 
matching biofilm positive tumors N1, N12-diacetylspermine once again displayed the highest 
fold change of 62.2 in the cancer tissue (Fig 3.1E).  N1-acetylspermidine, N1-acetylspermine 
and spermidine were also upregulated 6.5, 5.8, and 2.3-fold respectively.  When the 
correlative comparison was made between biofilm negative tumor tissues and their 
respective biofilm negative paired normal tissues, a lower 7.2-fold increase was detected for 
N1, N12-diacetylspermine, 3-fold for N1-acetylspermidine, 3.1-fold for N1-acetylspermine and 
1.4-fold for spermidine (Fig 3.1F).  While overall increased polyamine biosynthesis is 
detected in cancer tissues, this analysis highlights the additional increase associated with 
presence of a biofilm.   
To confirm the increased polyamine metabolite detection in biofilm positive cancer tissues 
we used LC-QqQ-MS and a quantitative targeted analysis approach to determine absolute 
concentrations of polyamines in the tissues.  We selected the following metabolites within 
the upregulated polyamine metabolic pathway: spermine, spermidine, N1-acetylspermine, N1-
acetylspermidine, N8-acetylspermidine and N1, N12-diacetylspermine (Fig. 3.2A).  This 
targeted approach with increased accuracy and specificity confirmed a general upregulation 
of the polyamine metabolites in cancer tissues compared to their paired normal colon 
tissues, independent of biofilm status (Fig. 3.2B, C.).  These more precise measurements 
highlighted the fold-change significance of N1, N12-diacetylspermine that had near zero 
values in the untargeted analyses of normal colon tissues (Fig. 3.1B compared to Fig 3.2B).  
Further, using this quantitative targeted approach direct comparison of biofilm positive and 
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negative cancer tissues revealed only significant upregulation of N1, N12-diacetylspermine in 
the biofilm positive cancer tissues (Fig. 3.2D).  Similar to the untargeted analysis, the two 
samples from the distal colon once again had the highest fold difference.  This reinforces 
that biofilm status, rather than geographic location in the colon, dictates the detected 
polyamine upregulation.  Using this targeted approach, the polyamines N1-acetylspermine 
and N1-acetylspermidine showed an increased trend in biofilm positive cancers but were not 
significantly upregulated as the initial untargeted results indicated, stressing the value of 
combined analyses for verification and validation.  
While biofilm association with polyamine upregulation in cancer tissues suggests a potential 
role in cancer progression, the analysis of biofilm presence on normal tissues can begin to 
give insight to any pro-oncogenic potential of this phenotype before epithelial cell 
transformation.  Importantly, the normal tissues which were concordantly biofilm negative 
or positive with their paired cancer tissues, revealed no significant changes in relative 
abundance of N1, N12-diacetylspermine and N1-acetylspermidine by untargeted 
metabolomics; however targeted analysis revealed that N1, N12-diacetylspermine and N1-
acetylspermine were significantly upregulated in the biofilm positive normal colon tissues 
compared to biofilm negative normal tissues obtained from colon cancer hosts (Fig. 3.2E). 
All but one biofilm negative paired normal tissues had a value of zero for N1, N12-
diacetylspermine, with an average concentration of 4.9 ± 4.3 fmol/mg tissue. In contrast, 
biofilm positive paired normal tissue averaged 0.6 ± 0.5 pmol/mg.  
In the human host, sperimine/spermidine acetyltransferase (SSAT) is required for acetylation 
of spermine to generate N1, N12-diacetylspermine, while bacterial species have been verified 
to contain alternative acetyltransferases [174-177].  Thus, the increased acetylated polyamines 
could be generated by host cellular proliferation and mucosal repair leading to increased 
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epithelial/mucosal SSAT expression, or through bacterial acetylation. To begin to delineate 
the source(s) of increased acetylated polyamine production, mucosal SSAT expression was 
examined by immunohistochemical staining and quantification (Fig. 3.3A,B, FigS3.1). No 
significant difference was detected in epithelial cell SSAT between tissues with and without a 
biofilm (cancer tissues or paired normal tissues) (Fig. 3.3B), suggesting that the upregulation 
in biofilm-covered tissues is not due to increased mucosal SSAT acetylation of polyamines 
by the host.   
We utilized nanostructure-initiator mass spectrometry (NIMS) imaging to clarify the spatial 
location of polyamine production on the biofilm positive tissues. This technology correlates 
the abundance of metabolites to their location within the tissue using a matrix-free 
nanostructured silicon surface which has initiator materials trapped inside nanopores, 
metabolites are desorbed from the tissue and placed onto the surface by laser 
irradiation[178,179]. Figure 3.3C shows NIMS metabolite intensity images for the 
polyamines in paired biofilm positive normal and cancer tissues. A consecutive tissue slice 
was stained for histology to verify tissue architecture, cancer, and normal cells (Fig. 3.3D). 
These results reveal enhanced detection of the acetylated metabolites at the mucosal edge of 
the cancer tissue further suggesting that the microbial biofilm could be contributing to the 
signal detected by MS. Overall levels of in situ polyamine concentrations (relative intensity in 
the total tissue section), consistent with the MS data, are higher in the cancer tissue than in 
normal tissue (Fig 3.3C). 
To further delineate the microbial vs. host source of the upregulated polyamine metabolites 
identified, we utilized tissue samples (normal and cancer tissues, three left-sided, six right-
sided pairs) collected from nine colon cancer patients treated with oral antibiotics 24 hours 
prior to surgery.  Although CRCs collected from the right colon are predicted to be biofilm 
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positive based on our previous report (CHAPTER 2, [172]), FISH analyses of right tumor 
and paired normal tissues from patients treated with antibiotics revealed no biofilms 
(Fig.3.4A), indicating that oral antibiotics are effective at clearing the microbial biofilm 
population within the mucus layer.  Additionally, microbial culture revealed little to no 
anaerobic or aerobic microbial growth on nutrient rich agar, suggesting that oral antibiotic 
treatment is effective at considerably lowering the cultivatable microbial load (Fig 3.4B). 
Considering that all right colon (cecum and ascending colon) cancers screened (n=17) were 
found to contain a biofilm, and the majority (88%, n=17) of left colon (transverse, distal and 
rectum) cancers were found to be biofilm negative, these samples offered a unique 
opportunity to clarify the potential microbial contribution independent of geographic 
location.  Comparison of right and left antibiotic treated cancer samples revealed no 
increased metabolites; therefore, cancer tissues lacking a microbial presence no longer retain 
the significant increase in polyamine metabolites (Fig S3.2A). Consistent with the non-
antibiotic treated samples, when all antibiotic treated cancers are compared to their paired 
normal tissues N1-acetylspermine, N1-acetylspermidine and N1, N12-diacetylspermine are 
increased in the cancer tissue (Fig S3.2B, Fig 3.2C). Importantly, proximal cancers from 
antibiotic treated patients had significantly less N1, N12-diacetylspermine than the biofilm 
positive cancers (Fig 3.4C).  Furthermore, there are no detectable polyamine metabolite 
differences between antibiotic treated proximal cancers and biofilm negative cancer tissues 
from patients that did not receive antibiotics prior to surgery (Fig 3.4D).  Collectively, these 
data reveal that antibiotic-treated cancers, even from the biofilm-prone right colon, are more 
metabolically similar to biofilm negative cancers than biofilm covered cancers. Ultimately 
suggesting that both host cells and microbial biofilms contribute to the global upregulation 
of polyamine metabolites in colon cancer. 
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To test the specificity of the polyamine metabolite changes to the cancer host, we examined 
proximal and distal colon biopsies collected from individuals undergoing routine screening 
colonoscopies.  None of these biopsies exhibited biofilms, and these individuals did not 
have colon cancer or inflammatory colonic disease.  No acetylated polyamines were detected 
using targeted metabolomics on biopsies from healthy individuals.  Further, proximal and 
distal biopsies did not have significantly different levels of spermine or spermidine, 
confirming that there are no baseline differences in polyamine levels due to geographical 
colon location (Fig S3.2C).  When the colonoscopy biopsies from healthy individuals were 
compared to the surgically resected paired normal tissues from CRC patients, spermine was 
significantly increased in the normal tissues from the cancer host (Fig 3.4E,F). Further, N1-
acetylspermidine levels were significantly increased in the biofilm-covered paired normal 
tissues from the cancer host compared to the biopsies from healthy individuals (Fig 3.4E).  
These results confirm past observations of cancer field-effect, whereby histologically normal 
tissue from a cancer host exhibits some cellular alterations, such as acetylated polyamines, far 
from the cancer site[180].        
 
3.4 Discussion 
Polyamines are essential metabolites necessary for core physiological processes, including 
cellular proliferation[173].  In the human colon, both host cells and the gut microbiota are 
capable of polyamine synthesis.  Several lines of evidence have reported that bacteria have 
evolved mechanisms to capitalize on the presence of polyamine molecules to increase 
virulence and optimize their fitness within the host[181].   In vitro studies have shown that 
increased levels of polyamines lead to enhanced proliferation of several mammalian cell 
lines, while a microbial report suggests that bacterial polyamine production drives biofilm 
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formation[173,182,183]. This study demonstrates, for the first time, that there is a direct 
correlation between bacterial biofilm formation on tissues from the cancer host and 
upregulation of N1, N12-diacetylspermine, a polyamine that may affect the growth of both 
cancer cells and the associated biofilm.  Although biofilms are found to be largely restricted 
to right-sided cancers, the two highest concentrations of N1, N12-diacetylspermine detected 
are from of biofilm positive left-sided cancers. This finding highlights the role of the biofilm, 
rather than the geographic location within the colon, in regulation of this polyamine 
metabolism. Association between increased polyamine levels and cancers have been reported 
in both animals and humans [173,184]. Increases in N1, N12-diacetylspermine, has been 
detected in several cancers including CRC[185,186], however, this is the first indication that 
the microbial metabolome is in part responsible for the production of this pro-oncogenic 
metabolite in a cancer setting.  Notably, no significant difference in epithelial SSAT 
expression was detected between tissues with and without a biofilm, as measured by 
histological scoring.  Further, NIMS analysis localizes a significant polyamine concentration 
at the mucosal surface where the biofilm resides.  While we cannot definitively attribute the 
increase in N1, N12-diacetylspermine to the bacteria comprising the biofilm, the data in this 
report strongly suggests a role for the mucosal-associated community.  We have recently 
demonstrated that the presence of a biofilm correlates with the pro-carcinogenic state of 
increased epithelial IL-6, pSTAT3 and epithelial proliferation (CHAPTER 2, [172]).    
 
Collectively, we propose a model whereby host and bacterial products act together to 
promote biofilm formation and cellular proliferation, creating conditions conducive to 
oncogenic transformation in colonic epithelial cells. Consistent with this hypothesis, studies 
have shown that ornithine decarboxylase (ODC), the first enzyme in the pathway leading to 
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polyamine synthesis, is affected by microbiota in human cancer cell lines [187].  
Furthermore, Helicobacter pylori can upregulate c-MYC leading to the activation of ODC[188].  
Alternatively, the increased cellular proliferation of biofilm-covered epithelium could 
increase the available pool of extracellular polyamines (that bacteria have evolved specialized 
transporters to take up) [181,183].  The upregulation of polyamines can enhance cancer 
growth, invasion and metastisis [182].  
A limitation of this work is that the temporal sequence of biofilm formation and cancer 
initiation has not been addressed. Therefore, it remains unclear whether biofilms directly 
induce tumorigenesis or if they are merely a consequence. To begin to approach this difficult 
question, a prospective study analyzing biofilm presence in healthy individuals undergoing 
routine colonoscopy would be required.  These samples would give us the capacity to 
identify mechanisms that biofilms may exert in the absence of a cancer environment.  
Unfortunately, no biofilm-covered biopsies from healthy individuals were assessed in this 
analysis.  Nevertheless, the data presented here adds to the growing body of evidence 
supporting different etiologies of disease between right and left cancers, which differ in their 
molecular and metabolic characteristics[65,189].  Furthermore, treatment implications may 
be extracted from this data. Both animal models and clinical trials utilizing inhibitors that 
block the polyamine metabolic pathway have resulted in unclear findings. However, focused 
targeting taking into consideration both polyamine production and biofilm interactions may 






3.5 Materials and Methods 
Materials 
Spermine, spermidine, N1-acetylspermine and N8-acetylspermidine were purchased from 
Sigma Aldrich (St. Louis, MO). N1-acetylspermidine and N1, N12-diacetylspermine 
dihydrochloride were kind gifts from Frank J. Gonzalez, National Cancer Institute, 
Bethesda, MD and Masao Kawakita, Tokyo Metropolitan Institute of Medical Science, 
Toyko, Japan, respectively. The anti-SSAT antibody was provided by Robert A Casero, 
Johns Hopkins Medical Institutions, Baltimore, MD. All other chemicals were of the highest 
chemical grade and purchased from Sigma Aldrich. 
Sample Collection 
Colon cancers and paired histologically normal tissues were collected from patients 
undergoing surgery at the Johns Hopkins Hospital. Tumor and normal tissues not required 
for pathologic diagnosis were preserved in Carnoy’s fixative or snap frozen in liquid nitrogen 
for analysis. Patients who received pre-operative radiation, chemotherapy or had a personal 
history of CRC were excluded. Pre-operative intravenous antibiotics were administered in all 
cases (cefotetan or clindamycin/gentamycin).  A subset of patients received oral antibiotics 
(neomycin and erythromycin) the day prior to surgery. 
Healthy control patients undergoing screening colonoscopy were recruited and signed 
informed consent. All patients underwent a standard mechanical bowel preparation. Mucosal 
biopsies from grossly normal colon were taken from the ascending (right) and descending 
(left) colon during the colonoscopy. Mucosal biopsies were rapidly preserved in Carnoy’s 
fixative or snap frozen in liquid nitrogen for analysis. Patients who had a personal history of 
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CRC, inflammatory bowel disease or were treated with antibiotics within the past three 
months were excluded. Patient metadata are in Tables 1 and 2. 
This study was approved by the Johns Hopkins Institutional Review Board. 
Fluorescent in situ hybridization 
The universal bacterial probe, EUB338 (5’GCTGCCTCCCGTAGGAGT3’), and nonsense 
probe NON338 (5’ACTCCTACGGGAGGCAGC), were synthesized and conjugated at the 
5’ end to Cy3 (Eub338) or Alexa488 (NON338) (Invitrogen Life Technologies). Universal 
probe was applied to 5 µm thick Carnoy’s-fixed paraffin-embedded tissue sections. The 
nonsense probe, NON338, was also applied to test for nonspecific binding. Successive 
sections were stained with Periodic acid Schiff (PAS) to confirm mucus presence and 
preservation.  
Slides were de-waxed following standard procedures and subjected to 10 minutes of 10 
mg/ml lysozyme in Tris buffer, followed by three rinses in Tris buffer. Eub338 
oligonucliotide probe was applied to slides at a concentration of 2 pmol/μl in prewarmed 
hybridization buffer (900 mM NaCl, 20 mM Tris pH 7.5, 0.01% SDS, 20% formamide). 
Slides were incubated at 46°C in a humid chamber for 2 hours, and washed at 48°C for 15 
minutes in wash buffer (215 mM NaCl, 20 mM Tris pH 7.5, 5 mM EDTA). Coverslips were 
mounted using ProLong Gold antifade reagent (Life Technologies) and slides were imaged 
using a Nikon E800 and imaged NIS elements solftware.   
Sample Preparation for Metabolomics 
For each sample, 10 mg of tissue was weighed and added to 1.5 mL centrifuge tubes 
containing 600µl ice cold acetone. Samples were vortexed for 30 seconds, snap frozen in 
liquid nitrogen for 1 minute, thawed for 3 minutes and sonicated for 15 minutes at 50oC. 
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Freeze-thaw cycles were repeated two more times before storing samples at -20oC for 1 
hour. Samples were centrifuged at 13,000 rpm for 15 minutes and the supernatant 
transferred to a new 1.5 mL centrifuge tube for storage at -20oC. The pellet was resuspended 
in 400 µL ice cold methanol/water/formic acid (86.5/12.5/1.0 v/v/v), vortexed for 30 
seconds and sonicated for 15 minutes at 50oC. The pellet samples were stored at -20oC for 1 
hour followed by centrifugation (13,000 rpm for 15 minutes). The supernatant was pooled 
with the supernatant collected earlier and dried down in a Speedvac for 4 hours. The samples 
were resuspended in 100 µl acetonitrile/water/isopropanol (50/40/10 v/v), sonicated for 5 
minutes at 50oC and stored at 4oC for 1 hour. The samples were finally centrifuged at 13,000 
rpm for 15 minutes and the supernatants transferred to glass HPLC vials for LC-MS 
analysis. These methods recover both hydrophobic and hydrophilic metabolites from the 
samples. 
Untargeted Metabolomics  
Samples were randomized and analyzed by high performance liquid chromatography-
electrospray ionization quadrupole time-of-flight mass spectrometry (HPLC-ESI-
QTOFMS). Samples (8 µL) were injected onto a reversed-phase 150 x 1.0 mm Zorbax 5µm 
C18 column (Agilent Technologies, Santa Clara, CA) using an Agilent Technologies series 
1200 HPLC with a gradient mobile phase of 0.1% formic acid (solution A) and acetonitrile 
containing 0.1% formic acid (solution B) at a flow rate of 20 µL/minute: 2% B for 5 minutes 
to 98% B at 50 minutes, held for 10 minutes at 98% B then re-equilibration at 2% B. MS was 
performed on an Agilent Technologies 6538 UHD Accurate Mass Q-TOF. The samples 
were analyzed in ESI positive mode. LC/MS data were processed using XCMS Online. 
XCMS applies a nonlinear retention time correction, performs peak-picking, feature 
identification and matches peaks across runs[190]. It reports integrated areas of each 
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detected peak in individual samples and calculates the Welch’s t test for two sample groups. 
For this study paired and unpaired non-parametric tests were carried out (Wilcoxon Rank 
Sum and Mann-Whitney). Features were listed in a feature table and as an interactive cloud 
plot, containing their integrated intensities (extracted ion chromatographic peak areas) 
observed fold-changes across the two sample groups, and p-values for each sample[191]. The 
default XCMS parameter set for HPLC-UHD-QTOFMS was used with tolerance for 
database search set to 30 ppm. Integration of METLIN to XCMS Online allowed for 
putative identification of metabolites. Identifications were then made by comparing retention 
time and tandem MS fragmentation patterns to the sample and a standard compound. 
Tandem MS experiments were carried out with the collision energy set to 20 eV and 
caused the fragmentation of the metabolites into a number of fragments specific for the 
metabolite. This fragmentation pattern combined with the retention time comparison to a 
standard allows for accurate identification. The full dataset is available as a public share on 
XCMS Online. 
Targeted Metabolomics of Polyamines 
For method development a number of column chemistries were tried and tested in acidic 
conditions to retain and resolve the polyamines including the Zorbax C18 (Agilent 
Technologies), Aminopropyl (Phenomonex, Torrance, CA) and ZIC-HILIC (SeQuant, 
Umea, Sweden); however the Scherzo SM-C18 column 150 x 0.5 mm 3µm (Imtakt, 
Philadelphia, PA) gave the optimal results. Samples (8 µL) were injected onto the column 
using an Agilent Technologies series 1200 HPLC with a gradient mobile phase of 5 mM 
ammonium acetate (solution A) and 50 mM acetate and acetonitrile (50/50 v/v) (solution B) 
at a flow rate of 20 µL/minute: 2% B for 5 minutes, to 17% B at 11 minutes, to 98% B at 
13.5 minutes, held for 5 minutes at 98% B then re-equilibration at 2% B. Targeted analysis 
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for quantitation of the polyamines were measured by using the above column conditions and 
selected reaction monitoring triple quadrupole mass spectrometry (Agilent 6410 QqQ-MS). 
The following quantifier and qualifier transitions were used for each metabolite: spermine: 
203.2 -> 112.1, 203.2 -> 129.1; spermidine: 146.2 -> 112.1, 146.2 -> 72.1; N1-
acetylspermine: 245.2 -> 100.1, 245.2 -> 112.1; N1-acetylspermidine: 188.2 -> 100.1, 188.2 -
> 72.1; N8-acetylspermidine: 188.2 -> 114.1, 188.2 -> 72.1; N1, N12-diacetylspermine: 287.2 -
> 100.1, 287.2 -> 171.1. The fragmentor voltage and collision energies were as follows: 
spermine: 110 V, 6 V (quantifier), 18 V (qualifier); spermidine: 107 V, 10 V (quantifier), 14 V 
(qualifier); N1-acetylspermine: 119 V, 18 V (quantifier), 18 V (qualifier); N1-acetylspermidine: 
107 V, 14 V (quantifier), 18 V (qualifier); N8-acetylspermidine: 119 V, 14 V (quantifier), 22 V 
(qualifier); N1, N12-diacetylspermine: 113 V, 14 V (quantifier), 22 V (qualifier).  
NIMS analysis 
NIMS substrates were prepared as previously described [179]. In brief, p-type silicon wafers, 
500 to 550 μm thick with 0.01 to 0.02 Ω cm resistivity (Silicon Quest International, Santa 
Clara, CA) were cut into 33 mm2 pieces. The wafers were soaked in Piranha solution 
(sulfuric acid and hydrogen peroxide (2:1)) overnight, washed thoroughly with nanopure 
water and then dried using nitrogen gas. Etching was carried out by clamping the wafer in a 
Teflon chamber. Gold foil was used for the anode and a platinum loop as the cathode; a 
25% ethanolic hydrogen fluoride solution was then added to the chamber. A BIO-RAD 
PowerPack1000 (Hercules, CA, USA) was connected and run at a constant-current mode 
(300 mA) for 30 minutes. The etched wafers were washed in methanol and evaporated to 
dryness using nitrogen gas. Bis(heptadecafluoro-1,1,2,2tetrahydrodecyl)tetramethyldisiloxane 
(Gelest, Morrisville, PA, USA) (100 μL) was applied to the surface of the chip and allowed 
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to sit at room temperature for 1 h before using nitrogen gas to remove excess from the 
surface. Tissue-Tek® Optimal Cutting Temperature (OCT) medium (Sakura Finetek, 
Torrance, CA) -embedded cancers were cut to 1-2 µm slices using a microtome and placed 
on top of the NIMS surface. A consecutive slice (5µm) was taken, applied to a Superfrost 
Plus microscope slide (Fisher Scientific, Signal Hill, CA) and stored at -80oC for histology. 
The NIMS chip was transferred to a room temperature vacuum for drying. Tissues were 
visibly dry within one minute. NIMS imaging data was acquired at 50 μm intervals using an 
AB/SCIEX 5800 TOF/TOF mass spectrometer in positive-mode. Images were analyzed 
using TissueView Software (Version 1.0) with a m/z range 50-400, bin size of 4 with 10819 
data points) 
SSAT immunohistochemical staining 
Immunohistochemistry was performed on tissue fixed in 10% formalin and paraffin-
embedded following standard procedures.  Sections were de-paraffinized and rehydrated 
through a xylene, ethanol-water gradient. Antigen unmasking was performed by steaming in 
high temperature target retrieval solution (Target Retrieval Solution; Dako) for 45 minutes. 
Endogenous peroxidase activity was quenched by incubation with peroxidase block for 5 
minutes at room temperature. Slides were incubated with an anti-SSAT antibody (Dr. 
Casero, 1:6000) overnight at 4°C. A horseradish peroxidase-labeled secondary antibody 
(PowerVision; Leica Microsystems) was applied for 30 minutes at room temperature. Signal 
detection was performed using 3,3’-diamino-benzidine (DAB) as the chromagen. Slides were 
counterstained with hematoxylin, dehydrated and mounted with glass coverslips using 




Tissue was collected following surgical resection for microbial cultivation in aerobic and 
anaerobic conditions.  Anaerobic tissue specimens collected in specialized transport media 
(Anaerobe systems) were washed twice with 0.016% DTT in saline prior to hand 
homogenization in saline under anaerobic conditions.  Tissue homogenate was diluted (100-
106) and plated on pre-reduced non-selective Brucella blood agar (Bru) plates. Plates were 
stored under anaerobic conditions at 37°C until colony forming unit counts could be 



























Figure 3.1. Untargeted liquid chromatography quadrupole time-of-flight mass spectrometry 
(LC-QTOFMS) metabolomics. (A) Cloud plot generated by XCMS Online showing 
dysregulated features between colon cancer and matched paired normal tissues (N=30, two-
tailed Wilcoxon matched-pairs signed rank test). Total ion chromatograms (TICs) for each 
sample can be seen on the plot; features whose intensity are increased in cancer tissues are 
shown on the top part of the plot as blue circles and features whose intensity decreases in 
cancer tissues are shown on the bottom part of the plot as green circles. Larger and brighter 
circles (features) correspond to larger fold changes and higher p-values respectively. (B) 
Corresponding relative abundance of N1, N12-diacetylspermine integrated from extracted ion 
chromatograms (EICs) (two-tailed Wilcoxon test), (C) Cloud plot comparing cancer tissue 
from biofilm negative patients (lower part of plot) to biofilm positive cancers from CRC 
patients (upper part of plot) (two-tailed Mann-Whitney test) (n=11 biofilm negative cancers, 
n=8 biofilm positive cancers). (D) Corresponding relative abundance of N1, N12-
diacetylspermine integrated from EICs (two-tailed Mann-Whitney test) **p<0.01. Also 
shown is a tandem MS spectrum of N1, N12-diacetylspermine in colon cancer samples and 
standard compounds. (E) biofilm positive normal tissues compared to their paired biofilm 
positive cancer tissues (N=7 tissue pairs examined) and (F) biofilm negative normal tissues 






























Figure 3.2. Biofilm effects on metabolites in colon tissues. (A) Scheme of polyamine 
metabolism. Enzymes involved include polyamine oxidase (PAO), spermidine/spermine N1-
acetyltransferase (SSAT), ornithine decarboxylase (ODC), histone acetyltransferase (HAT), 
spermidine synthase (SRM), spermine oxidase (SMO), spermine synthase (SMS).  (B-E) 
Targeted liquid chromatography triple quadrupole mass spectrometry (LC-QqQ-MS) 
metabolomics. Absolute concentrations of spermine, spermidine, N1-acetylspermine, N1-
acetylspermidine and N1, N12-diacetylspermine in: (B) paired normal and cancer tissues with 
biofilms (two-tailed Wilcoxon matched-pairs signed rank test, n=8 pairs) (C) paired normal 
and cancer tissues lacking biofilms (two-tailed Wilcoxon matched-pairs signed rank test, 
n=11 pairs) (D) cancers with or without biofilms (two-tailed Mann-Whitney test, n=9 
biofilm positive and n=11 biofilm negative) (E) paired normal tissues with or without 
biofilms from CRC patients (two-tailed Mann-Whitney test n=8 biofilm positive and n=11 
biofilm negative). Left-sided biofilm positive samples are indicated by empty red circle 
(cancers) or empty blue square (paired normal tissues) symbols. Error bars are SEM, 













Figure 3.3. Localization and quantification of SSAT and polyamines (A) SSAT IHC of 
cancer and paired normal tissues from patients with and without a biofilm (scale bar 50um) 
(B) Scoring of epithelial SSAT IHC in Cancers and paired normal tissues with (n=9) and 
without (n=11) a biofilm (C) Nanostructure-initiator mass spectrometry (NIMS) imaging on 
paired biofilm positive normal and cancer tissues showing spatial specificity of polyamines in 
tissues. Scale bars approximately 100µm. (D) Hematoxylin and eosin staining of a 
consecutive section of tissues displayed in (C) showing cancer and normal colon tissue 
orientation. *mucosal edge of cancer and normal tissue. Scale bars: 500 µm left column; 200 
µm right column. 
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Figure 3.4. Antibiotic-treatment clears biofilm from the mucosa and decreases polyamines. 
(A) FISH of all bacteria (red) displaying a bacterial biofilm on right cancer and paired 
normal tissue from a non-antibiotic-treated CRC patient, and no bacterial presence on a 
right cancer and paired normal from an antibiotic-treated patient. Tissues were 
counterstained with DAPI (scale bar 10 um). (B) Microbial culture data from patients 
treated with antibiotics (n=8) compared to non-antibiotic treated CRC patients (n=8). (C-F) 
Absolute concentrations of spermine, spermidine, N1-acetylspermine, N1-acetylspermidine 
and N1, N12-diacetylspermine in (C) right cancers from antibiotic-treated CRC patients 
(n=6) and cancers with biofilms (n=9) from non-antibiotic-treated colon cancer patients, 
(D) right cancers from antibiotic-treated colon cancer patients (n=6) and cancers without 
biofilms (n=11) from non-antibiotic-treated colon cancer patients, (E) colonoscopy biopsies 
from healthy subjects (n=8 biopsies, 4 each from the right and left colon) and paired normal 
tissues with biofilms from colon cancer patients (n=8), (F) colonoscopy biopsies from 
healthy individuals (n=8 biopsies, 4 each from the right and left colon) and paired normal 
tissues without biofilms from colon cancer patients (n=11). Left-sided biofilm positive 
samples are indicated by empty red circle (cancers) or empty blue square (normal tissues) 
symbols. All were analyzed by two-tailed Mann-Whitney test, error bars are SEM, *p<0.05, 








Figure S3.1. SSAT immunohistochemical analysis of CRC tissues. Images of control 
staining of (A) HCT116 cells stimulated with the polyamine analogue N1,N11-bis(ethyl) 
norpermine (first panel) displaying positive SSAT staining compared with unstimulated 
HCT116 (second panel) cells lacking any SSAT. (B) SSAT staining of cancer tissue with 
(first panel) and without (second panel) primary antibody. Immunohistochemical 0-3 scoring 
system (C) with representative cytoplasmic staining intensities. Selected inserts are displayed 








Figure S3.2. Further comparison of antibiotic-treated cancer tissues and normal 
colonoscopy biopsies from healthy individuals. Absolute concentrations of spermine, 
spermidine, N1-acetylspermine, N1-acetylspermidine and N1, N12-diacetylspermine in (A) 
left- and right-sided cancers (n=9, 3 left-sided, 6 right-sided) from antibiotic-treated colon 
cancer patients, (B) surgically-resected normal and cancers (n=9 tissue pairs) from 
antibiotic-treated colon cancer patients, and (C) left- and right-sided normal colonoscopy 
biopsies from healthy individuals (n=4 right and left colon biopsy pairs from 4 patients). 
Two-tailed Wilcoxon matched-pairs signed rank test. Error bars are SEM, *p<0.05, 




Table 3.1. Colorectal cancer patient metadata 
 
*Patient received antibiotics day prior to surgery 








Patient ID Patient Type Age Sex Race Tumor Site Biofilm Stage Size (mm) Histology
3711* Surgical CRC 45 M Caucasian Cecum ND** 2 145.0 Adenocarcinoma
3727 Surgical CRC 44 F African American Cecum ND** 3 50.0 Adenocarcinoma
3773* Surgical CRC 58 F African American Cecum No 4 35.0 Adenocarcinoma
3979 Surgical CRC 77 F African American Cecum Yes 3 35.0 Adenocarcinoma
3989* Surgical CRC 41 F Caucasian Cecum No 4 85.0 Mucinous Adenocarcinoma
3728 Surgical CRC 69 M Caucasian Ascending Yes 1 87.0 Adenocarcinoma
3731 Surgical CRC 74 M Caucasian Ascending Yes 2 30.0 Adenocarcinoma
3744* Surgical CRC 68 M Caucasian Ascending No 4 80.0 Adenocarcinoma
3753 Surgical CRC 49 F African American Ascending Yes 4 47.0 Mucinous Adenocarcinoma
3754 Surgical CRC 67 F African American Ascending Yes 2 30.0 Adenocarcinoma
3762 Surgical CRC 73 M Caucasian Ascending Yes 4 54.0 Adenocarcinoma
3779 B* Surgical Polyp 74 F Caucasian Ascending No NA 42.0 Tubulovillous adenoma
3780* Surgical CRC 78 F Caucasian Ascending No 4 40.0 Adenocarcinoma
3991* Surgical Polyp 70 M Caucasian Ascending No NA 31.0 Tubular adenoma
3994* Surgical CRC 82 F Caucasian Ascending No 2 30.0 Mucinous Adenocarcinoma
3987 Surgical CRC 66 F Caucasian Ascending Yes 2 50.0 Mucinous Adenocarcinoma
3770 Surgical CRC 71 M Caucasian Hepatic Flexure No 1 35.0 Adenocarcinoma
3774 Surgical CRC 45 M Asian Hepatic Flexure Yes 2 45.0 Adenocarcinoma
3752 Surgical CRC 73 F Caucasian Transverse No 2 25.0 Adenocarcinoma
3976 Surgical CRC 52 F Caucasian Transverse No 1 20.0 Mucinous Adenocarcinoma
3768 Surgical CRC 45 M African American Transverse No 4 42.0 Adenocarcinoma
3718 Surgical CRC 60 M Caucasian Splenic Flexure ND** 2 35.0 Adenocarcinoma
3769 Surgical CRC 78 F African American Splenic Flexure No 3 60.0 Adenocarcinoma
3992 Surgical CRC 91 F Caucasian Splenic Flexure Yes 2 45.0 Adenocarcinoma
3749 Surgical CRC 39 M Caucasian Sigmoid No 3 50.0 Adenocarcinoma
3756 Surgical CRC 54 M Caucasian Sigmoid Yes 4 45.0 Adenocarcinoma
3766 Surgical CRC 56 F Caucasian Sigmoid No 4 55.0 Adenocarcinoma
3786* Surgical CRC 56 M Caucasian Sigmoid ND** 4 10.0 Adenocarcinoma
3977 Surgical CRC 38 F Caucasian Sigmoid No 1 50.0 Adenocarcinoma
3712 Surgical CRC 79 F Caucasian Rectosigmoid ND** 3 65.0 Adenocarcinoma
3721 Surgical CRC 55 F Caucasian Rectosigmoid ND** 2 50.0 Adenocarcinoma
3736 Surgical CRC 56 M African American Rectosigmoid ND** 3 53.0 Adenocarcinoma
3760 Surgical CRC 29 F Caucasian Rectosigmoid No 2 80.0 Adenocarcinoma
3788* Surgical CRC 52 M Caucasian Rectosigmoid No 4 40.0 Adenocarcinoma
3719 Surgical CRC 31 F Asian Rectum ND** 2 65.0 Adenocarcinoma
3735 Surgical CRC 64 M Caucasian Rectum No 3 70.0 Adenocarcinoma
3759* Surgical CRC 87 F Caucasian Rectum No 4 45.0 Adenocarcinoma
3978 Surgical CRC 90 F Caucasian Rectum No 1 27.0 Mucinous Adenocarcinoma
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Patient ID  Age Sex Race Bowel Prep Biopsy Site Biofilm
52 43 F Caucasian NuLytely Prep Descending No
Ascending No
53 47 M Caucasian GoLytely Prep Descending No
Ascending No
54 55 M Caucasian NuLytely Prep Descending No
Ascending No





Microbial associations  
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4.1 Abstract 
Familial adenomatous polyposis (FAP) is a dominantly inherited condition characterized by a 
germline mutation in the adenomatous polyposis coli (APC) tumor suppressor gene that 
confers a 100% lifetime risk of developing colorectal cancer (CRC). It remains unclear what 
causes the accumulation of additional mutations yielding CRC, however, recent evidence has 
emphasized contributions by the gut microbiome. Abnormalities have been reported 
regarding the colonic microbiome of individuals with sporadic CRC; however, limited 
microbiome analyses of individuals with hereditary CRC exist. We investigated the 
composition and microbial organization of the FAP microbiome.  Sequence analysis of 
mucosal samples revealed enrichment of Bacteroides on FAP polyps when compared to 
healthy control subjects.  Further, fluorescent in situ hybridization (FISH) of mucosal tissues 
revealed conserved and distinct bacterial biofilms throughout the colon, comprised 
predominately of Escherichia coli and Bacteroides fragilis, adherent to both polyps and 
histologically normal tissue. These findings were supported by semi-quantitative microbial 
culture data revealing increased detection of E. coli and B. fragilis on mucosal tissue from FAP 
patients compared to healthy subjects. Further, the oncogenic toxins Colibactin (from the E. 
coli pks pathogenicity island) and Bacteroides fragilis toxin (BFT), known to be expressed by 
these two organisms, were highly enriched in FAP patients (68%, n=25 and 60%, n=25, for 
pks+ E. coli and ETBF, respectively) when compared to healthy subjects without FAP (22%, 
n=23 and 30%, n=23, for pks+ E. coli and ETBF, respectively). Interestingly, if any 
individual, FAP or a healthy subject, was colonized by one of these organisms they likely 
harbored the other (co-colonization 52%, n=25, for FAP and 22%, n=23 for healthy 
subjects). Preliminary mouse studies of co-colonization indicate that these two organisms 
may act additively to increase DNA damage and colitis in WT mice. These data suggest that 
 100 




Colorectal cancer (CRC) is one of the most common malignancies worldwide, with an 
annual incidence of 1.2 million and mortality of over 600,000 [1].  It is widely understood 
that CRC develops through a sequential accumulation of mutations that facilitate the 
transition from normal mucosa, to adenoma, to adenocarcinoma.  Greater than 90% of cases 
occur in individuals with little or no genetic risk, however, a significant minority 
(approximately 5% of cases) occur as a result of an inherited mutation [4]. One such 
hereditary condition, Familial Adenomatous Polyposis coli (FAP), is caused by germline 
mutations in the APC gene. Over 700 different mutation sites have been identified, leading 
to variable onset development of multiple adenomas (polyps) throughout the colon and 
rectum. Individuals with this genetic defect are born with their first mutation in the 
transition to CRC, and as additional mutations accumulate, hundreds to thousands of 
colorectal polyps develop.  Environmental factors contributing to these mutations are an 
area of immense interest and may be similar to those in the development of sporadic CRC. 
In particular, bacterial initiators and promoters of CRC progression have long been 
proposed [136].  
The human colon coexists in close proximity to trillions of bacteria that collectively 
constitute the colonic microbiome. Luminal bacteria are segregated from the host by a dense 
mucus layer that extends throughout the large intestine, preventing direct contact with 
epithelial cells [133]. In a healthy state this protective coating serves to promote tolerance of 
foreign antigens, limiting mucosal inflammatory responses; In contrast, persistent bacterial 
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breaches of the colonic mucus layer with, in some cases, biofilm formation fosters chronic 
mucosal inflammation [134]. Colonic biofilms characterize the disease states of Crohn’s, 
ulcerative colitis, self-limiting colitis and have recently been associated with sporadic 
colorectal cancer (CHAPTER,[172]).  The work presented in this chapter tests the 
hypothesis that FAP patients would share a similar dysbiosis in microbial associations. 
 
4.3 Results 
We investigated the intestinal microbiome composition and spatial arrangement in patients 
with known familial polyp syndromes undergoing surgery at Johns Hopkins Hospital. All 
patients had a phenotype consistent with familial polyposis and a subset underwent genetic 
counseling and mutational analysis confirming a mutation in the APC gene (Table S4.1). To 
conduct our analyses, tissue not needed for clinical evaluation was collected from sites 
throughout the colon (polyp and grossly normal tissue) and preserved in Carnoy’s fixative 
(n=6 cases, n=22 controls) or snap frozen (n=23 cases, n=22 controls).     
Microbial 454 sequence analysis was conducted using DNA extracted from the mucosal 
surface of polyps and paired normal tissue from four FAP patients harboring three different 
germline mutations (1 MYH-attenuated phenotype, 2 APC, and 1 Juvenile Polyposis(JP)) 
(Table S4.1). Results were compared with a parallel sequence analysis (previously reported) 
of colonoscopy biopsies collected from 10 healthy volunteers as well as tumor and paired 
normal tissue collected from 28 patients with sporadic CRC (CHAPTER 2, [172] ) (Fig 
4.1A).  Despite the limited number of samples analyzed, notable trends were observed. FAP 
patients were found to have bacterial populations of predominantly Bacteroides on polyp 
mucosa.  The Bacteroides levels were significantly increased when compared to sporadic CRC 
patients (tumor or normal mucosa) and normal mucosal biopsies collected from healthy 
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subjects (Fig 4.1 B).  Further, specific species enrichment of Prevotella sterocorea was identified 
on FAP polyp mucosa as compared to mucosal biopsies from healthy subjects (Fig 4.1). 
FAP polyps displayed a significant decrease in Proteobacteria (both Gammaproteobateria and 
Betaproteobacteria) when compared to normal mucosal biopsies from healthy controls (Fig 
4.1E).  There were no differentially abundant taxa identified at any taxonomic level between 
polyps and their respective paired normal tissues from any FAP patient. This is in contrast to 
sporadic CRC tumor epithelium that is characterized by a progressive microbial dysbiosis 
when compared to paired normal mucosa; namely sequences of sporadic CRC mucosa is a 
complete subset of its paired normal in 52% of individuals, with particular enrichment of 
Fusobacteria. In our sample set, only the JP patient had detectable Fusobacteria (F. necrophorum) 
present on a polyp (>63% of total reads were F. necrophorum) and normal flanking tissue 
(>16% of total reads were F. necrophorum) collected from the left colon, whereas Fusobacteria 
was largely absent from the polyp and normal flanking tissue in the right colon of this 
patient (<0.3% of sequencing reads) (Fig4.1A).  No detectable Fusobacterium reads were 
identified on the mucosa (polyp or normal) or in the stool of the three additional FAP 
patients.  
Of interest, stool was collected and sequenced from two sites (ascending and descending) 
from the FAP patient with the MYH mutation along with sequencing of mucosa from each 
site.  Analysis of the two stool samples from this individual revealed that the luminal stool 
population was dynamic along the GI tract.  Strikingly, the local stool microbiome reflected 
the mucosal population from the site of collection rather than stool collected from a 
different position along the gastrointestinal tract; stool from the ascending colon was more 
similar to the ascending mucosa than to stool collected in the descending colon and vice 
versa (Fig.4.1A).      
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In addition to sequence analysis, the spatial arrangement of bacteria on the colonic 
epithelium is also of interest as our group recently identified invasive polymicrobial bacterial 
biofilms on sporadic CRC (CHAPTER 2, [172]).  In sporadic CRC, biofilms were detected 
on all tumors and paired normal tissues from the right colon (proximal to the hepatic 
flexure), as well as a subset of tumors and paired normal tissues from the left colon (distal to 
the hepatic flexure).  Further, biofilms were associated with decreased crypt E-cadherin, 
increased epithelial cell IL-6, pSTAT-3, polyamine metabolites and proliferation, all potential 
contributors to malignant transformation (CHAPTERS 2 & 3, [172]). Herein we screened 
surgically resected tissue collected along the axis of the colon (cecum to rectum) from six 
FAP patients (Table 4.1) to evaluate bacterial biofilms. Polyps and macroscopically normal 
tissue were labeled with a FISH probe (EUB338) designed to recognize 16s ribosomal RNA 
of all bacteria. Four of the six FAP patients exhibited a bacterial biofilms scattered along the 
colonic axis (Fig 4.2A,B, FigS4.2).  Unlike biofilms detected on sporadic CRC that are 
continuous along the mucosal surface, FAP tissue displayed patchy biofilm formation with 
bacterial mucus invasion spanning 200-700 linear um on approximately 70% of surgically 
resected colon specimens from four of the six patients. Biofilms were not restricted to 
polyps, nor did they display geographic preference within the colon as observed in sporadic 
CRC (Table 4.1, FigS4.2, FigS4.3).  Of note, biofilms were not detected on tissues (polyp or 
paired normal) from the individual with juvenile polyposis, a condition where polyps never 
transition to cancer (FigS4.3). Biofilms were also not detected on the colon of an individual 
that received oral antibiotics 24 hours before surgery, a treatment known to clear mucosal 
associated biofilms (CHAPTER 2)(FigS4.3).  
Specimens found to contain a biofilm were further screened by additional probes designed 
to recognize the major phyla detected in biofilms of sporadic CRC: Bacteroides/Prevotella, 
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Proteobacteria, Lachnospiraceae, and Fusobacteria (Table S4.3). Interestingly, the biofilms of FAP 
patients were comprised most prominently (~70%) of Proteobacteria (Fig4.2B), a minority 
member of the FAP microbiome based on the 454 sequence analysis. The major group 
identified through sequence analysis, Bacteroides, was also detected, however it was found to 
make up 5-25% of the biofilms (Table 4.1). Neither Fusobacteria nor Lachnospiraceae were 
detected by FISH. Through additional, more specific probe sets (Table S4.3), the 
predominant biofilm members were identified as E. coli and B. fragilis (Fig 4.2B). Similar to 
the biofilms on the normal tissue of sporadic CRC patients, epithelial cell invasion by the 
biofilm community members was observed sporadically on all patients harboring a biofilm 
(Fig 4.2C).   
Semi-quantitative microbial culture analysis was carried out to determine the overall relative 
abundance of E. coli and B. fragilis on mucosal FAP samples. Mucosal tissue was 
homogenized and serial dilutions were cultured on selective Bacteroides Bile Esculin agar 
(Bacteroides) or MacConkey plates (Lactose-fermenting Enterobacteriaceae). Colony forming 
units (CFU) per mm2 FAP tissue were compared to CFU per mm2 on tissues collected from 
control subjects. From each FAP patient, polyps and corresponding normal tissue, and from 
control subjects tissue from both the left and right side colon were processed and the 
combined results of each patient were analyzed. Consistent with FISH analysis, cultivatable 
Bacteroides and Lactose-fermenting Enterobacteriacae were significantly increased on FAP 
tissues when compared to control subjects regardless of the tissue collection site (Fig 4.2D).   
Strong experimental evidence exists supporting the oncogenic potential of molecular 
subtypes of both E. coli and B. fragilis [47,192]; the two dominant biofilm members identified 
in direct contact with host epithelial cells in our FAP patients.  E. coli containing the pks 
pathogenecity island, which encodes the genes responsible for synthesis of the colibactin 
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genotoxin, induces DNA damage in vitro and in vivo along with tumorigenesis in AOM/IL10 
deficient mice[47].  Additionally, enterotoxigenic Bacteroides fragilis (ETBF) induces multiple 
tumors in the distal colon of APC mice, a CRC mouse model that carries a truncation 
mutation in APC [192].  
In addition to experimental evidence, human epidemiological studies have associated both 
organisms (ETBF and pks+ E. coli) with inflammatory bowel disease and sporadic colorectal 
cancer [47,54,193,194].  Thus, we screened banked frozen mucosal tissues from 25 FAP 
patients (2 polyps and 2 paired normal tissues per patient when available) and 22 healthy 
subjects (1 ascending and 1 descending biopsy per subject) for the presence of pks+ E. coli 
and ETBF.  The mucosa of FAP patients was significantly associated with pks+ E. coli (68%, 
n=25 patients) and ETBF (60%, n=25) when compared to mucosa of healthy subjects (22% 
pks+ E. coli and 30% ETBF+, n=23) (Table 4.2).  There was no preferential association 
between the presence of ETBF or pks+ E. coli on polyp mucosa vs. paired normal mucosa 
from FAP patients (Fig S4.3).  Typically, when a mucosal sample was identified as having 
pks+ E. coli or ETBF, the additional mucosal specimen(s) from that subject was also positive 
(73% for pks+ E. coli, 59% for ETBF), similar to our recently published results for BFT in 
sporadic CRC patients [194] .  Even more noteworthy, if a patient had pks+ E. coli, there was 
a high likelihood of also carrying ETBF; this was the case in both FAP patients and healthy 
control subjects (Table 4.2).   
The high frequency of double colonization with pks+ E. coli and ETBF, independent of 
disease state, highlights the importance of understanding the potential effects on the host of 
simultaneously harboring these two oncogenic organisms.  To this end, we characterized 
specific pathogen free (SPF) C57BL/6J mice co-inoculated with a pks+ E. coli isolated from 
an FAP patient (PL1) and a laboratory ETBF strain (086-5443-2-2) used in past tumor 
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mouse studies.  Initially, three FAP pks+E.coli isolates and the canonical NC101 strain 
utilized in murine tumor experiments were characterized in C57BL/6J. Histopathology was 
assessed at seven days post inoculation to detect acute colitis and the most virulent pks+ E. 
coli isolate (PL1) was selected for subsequent co-colonization experiments (Fig S4.3).  Co-
colonization experiments were analyzed at seven days post-colonization. Mice were assessed 
for DNA damage and inflammatory cytokines as compared with singly infected mice 
colonized by just ETBF or pks+ E. coli as well as sham mice.  Co-colonized mice had 
markedly increased DNA damage along the entire length of the colon, when compared with 
singly colonized mice as detected by phosphorylated histone variant H2AX (γH2AX) (Fig. 
4.3A).  Quantification of percentage of positive cells per crypt revealed that γH2AX was 
significantly increased when compared to mice singly infected with either pks+ E. coli or 
ETBF (Fig 4.3 B). Further, analysis of inflammatory cytokines revealed significant 
upregulation of iNOS and IL1-beta mRNA in co-infected mice when compared to singly 
infected mice (Fig 4.3 C, D).                       
4.4 Discussion 
Here we found that individuals with hereditary cancer, FAP, harbor a unique microbiome 
with altered epithelial associations.  Individuals with FAP harbor bacterial biofilms along the 
length of the colon comprised predominately of E. coli and B. fragilis in direct contact with 
the mucosa, with intermittent invasion of epithelial cells. Microbial culture analysis of 
mucosal samples from FAP vs. normal control subjects supports increased Bacteroides and 
Enterobacteriaceae populations on FAP mucosa.   
While, sequencing results were not consistent with the FISH and culture data, the sample 
size and tissue processing methodology could explain the differences observed. Further, 
oncogenic members of these species, pks+ E. coli and ETBF, were significantly associated 
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with FAP patients when compared to healthy subjects. The close proximity of biofilm 
members to host epithelium highlights the potential for this population to transfer 
oncogenic toxins directly to the epithelium.  The effect of co-colonization with these two 
organisms revealed a synergistic increase in DNA damage and inflammatory cytokines.  
Together these data support the notion that FAP patients harbor mucosal-associated 
members of the microbiota may act in consort to increase DNA damage and inflammation.   
Analyses of the CRC microbiome have revealed distinct microbial communities when 
compared to healthy individuals.  While specific species have been associated with CRC 
there has been no consensus what microbial members are important.  Speculations that 
polymicrobial contributions drive CRC have been proposed, suggesting that combinations of 
specific species may act in consort to promote tumorigenesis [170,195,196]. To our 
knowledge this is the first data, that links the carriage of one oncogenic organism with 
another in a cancer host.  The preliminary analysis of co-infection with more than one 
putative oncogenic agent in mice strongly suggests that two organisms may act together to 
lead to increased pathology. Further exploration of the tumorigenic potential of co-
colonization with these two organisms in murine models of carcinogenesis is underway. 
 
4.5 Materials and Methods 
Patient selection and Sample acquisition 
Polyps and paired normal tissues were collected from patients with Familial Polyposis 
undergoing surgery at Johns Hopkins Hospital. All patients had a phenotype consistent with 
familial polyposis and a subset underwent genetic counseling and mutational analysis. Two 
bowel preparations were routinely used and recorded (mechanical bowel preparation 
[MiralaxTM], or Fleet Phospo-sodaTM enema), pre-operative intravenous antibiotics were 
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administered in all cases (cefotetan or clindamycin/gentamycin) immediately preceding 
surgery. One patient received pre-operative oral antibiotics as noted in the patient metadata 
(Table S4.1). Normal control mucosal biopsies and surgically resected colon from grossly 
normal tissue were collected from individuals without a history of CRC, inflammatory bowel 
disease, or antibiotic usage within three months (designated herein as control subjects) 
(Table S4.2).  All tissue not needed for pathologic diagnosis was rapidly preserved in 
Carnoy’s solution, RNAlater, anaerobic transport media or snap frozen for subsequent 
analysis. 
This study was approved by the Johns Hopkins Institutional Review Board. All samples were 
obtained in accordance with the Health Insurance Portability and Accountability Act 
(HIPAA). 
Sample Preparation for Sequencing 
Samples were prepared as previously described (CHAPTER 2, [172]).  Briefly, mucosal 
samples collected from FAP polyp, FAP paired normal tissues, surgically resected control 
normal tissues, and colonoscopy biopsies were collected in the pathology or endoscopy 
suites and immediately placed in RNAlater (Qiagen Inc. Germantown, MD) and stored at -
80oC.  Tissue samples were incubated at 95oC in ASL buffer with frequent vortexing to 
remove bacteria from the epithelial surface. Following the dislodging of mucosal associated 
bacteria, supernatant was removed and cells were thoroughly lysed using pressure lysis and 
DNA was extracted using the QIAamp DNA Stool Kit (Qiagen). The V3-V5 region of 
bacterial 16S rDNA was amplified and sequenced following the procedures described by the 
Human Microbiome Project standard protocol 
(http://www.hmpdacc.org/doc/16S_Sequencing_SOP_4.2.2.pdf). Briefly, the V3-V5 region 
of 16S rDNA was amplified with PCR primers (357F 5’ CCTACGGGAGGCAGCAG 3’ 
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and 926R 5’ CCGTCAATTCMTTTRAGT 3’) that were appended with Roche 454 Titanium 
FLX library adapter sequences. All B-adapter primers were identical, while A-adapter 
primers also contained a unique barcode of 5-10 nucleotides to allow indexing of individual 
samples. Each sample was PCR amplified and purified.  Purified DNAs were quantified 
using the 454 FLX Library Quantification Kit (KAPA Biosystems Inc. Woburn, MA) and 
pooled for sequencing in equal molar quantity.  
Sequence data analysis 
Raw sequence reads were analyzed as previously described (CHAPTER 2, [172]).  Briefly, 
samples were identified using their barcodes, trimmed and filtered for quality and length 
(minimum 150 bp) using the QIIME package (v1.6.0). High quality reads were organized by 
sample and error-corrected using the Acacia tool (v1.52), de novo UCHIME (v4.2.40), and 
RDP Bayesian classifier (v2.5). The final high-quality contaminant-free dataset was then 
submitted to the CloVR-16S pipeline (v1.1) for diversity estimation, taxonomic 
characterization and comparative analysis of sample groups of interest. Downstream analysis 
included clustering of sequences into species-level OTUs (95% identity threshold), 
taxonomic assignment of OTU representatives and beta-diversity estimation. Pipeline runs 
were executed using CloVR (v2012.11.16) on the DIAG academic cloud 
(http://diagcomputing.org).  
Fluorescent in situ hybridization 
Carnoy’s fixed, paraffin-embedded tissues were sectioned to 5 µm thickness and de-waxed 
following standard procedures.  Sections were stained with Periodic acid Schiff (PAS) to 
confirm mucus presence and preservation and successive sections were hybridized with the 
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Eub338 universal bacterial probe and with a nonsense probe to test for nonspecific binding 
of probes. Slides were imaged using a Nikon E800 microscope with NIS elements software.  
Samples that were determined to have a bacterial presence by universal probe were next 
analyzed by a more specific probe set synthesized and conjugated at the 5’ end to the 
fluorophores listed in Table S3 (Life Technologies). Probes were applied to slides at a 
concentration of 2 pmol/ul of each probe in prewarmed hybridization buffer (900 mM 
NaCl, 20 mM Tris pH 7.5, 0.01% SDS, 20% formamide). Slides were incubated at 46°C in a 
humid chamber for 2 hours, and washed at 48°C for 15 minutes in wash buffer (215 mM 
NaCl, 20 mM Tris pH 7.5, 5 mM EDTA).  Slides were mounted using ProLongGold 
antifade reagent (Life Technologies).           
Biofilm quantification 
Bacterial biofilms were quantified for longitudinal distance along epithelium, depth, and 
density using slides hybridized with the universal bacterial probe (Table S4.3). When present, 
up to five biofilm measurements were taken of the entire longitudinal length of biofilm along 
the surface of the epithelium (some samples did not have five patches of biofilm, in these 
cases all present biofilms were measured). The average of five measurements of biofilm 
depth was taken from five tissue samples per patient.  Relative biofilm species quantification 
was performed using tissues hybridized with the universal bacterial probe along with B. 
fragilis and E. coli species specific probes (Table S4.3). One specimen per sample was selected 
for E. coli and B. fragilis relative quantification. Images were taken at 100x magnification and 
individual bacterial cells (all bacteria, E. coli, and B. fragilis) in a 10x10 µm space were 
counted. Five 10x10 µm boxes were counted per patient to determine the relative biofilm 
composition as a percentage. 
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Microbial Culture 
Enterobacteriaceae and Bacteroides 
In the pathology suite, tissue for culturing (8mm punches) was rapidly enclosed in anaerobic 
transport media to maintain the anaerobic environment required for Bacteroides. Tissue of 
both polyps and normal tissue of FAP patients and left and right-sided tissue of surgery 
controls was washed and homogenized in an anaerobic hood as described previously [194]. 
In short, after homogenization, serial dilutions (100-106) of the tissue homogenate were 
plated on Bacteroides Bile Esculin (BBE) agar for selective culturing of Bacteroides. 
Subsequently, BBE plates were incubated in an anaerobic incubator for 48 hours and single 
colony forming units (CFU) were assessed on plates with separate single colonies. Similarly, 
serial dilutions of the tissue homogenates were plated on MacConkey agar and incubated for 
24 hours in an aerobic incubator. Subsequently, the CFU of single pink colonies (Lac+ 
Enterobacteriaceae) was assessed. CFUs of both polyp and normal tissue of FAP patients was 
compared to CFUs of left and right-sided control tissue for both Bacteroides and 
Enterobacteriaceae with Mann-Whitney U statistics.  
Detection of pks E. coli and ETBF 
Tissue stored at -80°C was utilized for microbial culture and selective amplification and 
identification of E. coli and B. fragilis isolates.  Two to four mucosal samples per patient were 
available for microbiology culture analysis (metadata table S4.1 and S4.2). An approximately 
3mm diameter punch of mucosal sample from surgically-resected control tissue, FAP polyp, 
FAP paired normal, or colonoscopy biopsy was placed in tryptic soy broth (TSB) or peptone 
yeast glucose bile broth (PYGB) and grown in aerobic or anaerobic conditions, respectively, 
at 37°C for 48 hours.  Microbial growth was pelleted and an aliquot was preserved for PCR 
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detection of clbB and E. coli (TSB culture) and bft and B. fragilis (PYGB culture). The 
remaining pellet was diluted and plated on semi-selective agar for single colony 
identification; aerobic TSB culture was plated on MacConkey plates and anaerobic PYGB 
culture was plated on BBE plates.  A total of fifty Lac + or bile-esculin + colonies were 
selected for PCR from each sample.  PCR detection was performed using clbB primers 
(Forward: GCA ACA TAC TCG CCC AGA CT, Reverse:  TCT CAA GGC GTT GTT 
GTT TG) or bft primers (Forward: GCG AAC TCG GTT TAT GCA GT, Reverse: GTT 
GTA GAC ATC CCA CTG GC).   
Mouse Experiments 
 Specific pathogen free (SPF) C57BL/6J (Jackson Laboratories, Bar Harbor, ME) mice were 
utilized for colonization experiments.  Four-week-old mice were given water containing 500 
mg/L cefoxitin for 48 hours, and inoculated by oral gavage with 108 ETBF, 108 pks+ E. coli, 
or a mixture containing 108 of each strain 24 hours after antibiotic water was removed.  
Colonization was confirmed by collection and cultivation of stool on selective media 
(MacConkey plates or BHI plates (with 10µg/ml clindamycin and 200 µg/ml gentamicin)) 
48 hours after inoculation.          
Immunohistochemistry 
Formalin-fixed (10%), paraffin embedded tissues were sectioned (5µm) and stained.  Slides 
were de-paraffinized and rehydrated following standard procedures.  Slides were steamed in 
citrate buffer for 45 minutes, and allowed to cool to room temperature, followed by blocking 
of endogenous peroxidase activity for 10 minutes.  Slides were blocked for 30 minutes in 
10% normal goat serum, followed by primary antibody application overnight (1/500 rabbit 
anti-γH2AX [Bethyl Laboratories, IHC00008]).   Slides were incubated with HRP for 30 
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minutes followed by DAB chromogen for 10 minutes. All sections were counterstained with 
hematoxylin prior to mounting. 
Immunohistochemistry quantification 
Nine crypts were selected for γH2AX quantification; three each from the proximal, middle, 
and distal mouse colon.  Positive cells (containing 3 or more nuclear foci) were counted 
along with total number of cells in the crypt and a resulting percentage was determined. Cells 
were counted in a blinded manner.     
Quantitative real-time PCR 
An approximately 200 mg segment of distal mouse colon was processed for RNA isolation 
immediately following removal of the colon.  Tissue was homogenized by bead beating in 
buffer ALS (Qiagen) and then run through a tissuelyzer column (Qiagen). The resultant 
solution was utilized for RNA extraction with RNeasy kit according to the manufacturer’s 
recommended procedures. Transcription to complementary DNA was carried out using 
superscript III (Invitrogen).  All qPCRs were carried out in triplicate with TaqMan 
primer/probes for IL-17a, IL-6, IFNγ, Nos2 and18s (as reference gene), and TaqMan 2x 
mastermix (Applied Biosystems).   PCR conditions were for 48°C for 30 minutes, 95°C for 
10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The level 





Figure 4.1 16s sequence analysis of FAP patients. (A) Histogram of bacterial species 
detected on mucosal tissues and stool from 4 FAP patients harboring three different 
germline mutations. Asterisks denote stool samples collected from the left or right colon; 
bacterial stool populations are dynamic sharing more similarities with the local mucosa than 
stool in a different location along the colonic axis. Fusobacterium necrophorum was the only 
Fusobacterium species detected and was identified on only one of the four patients (B, C and 
D) Relative abundance of Bacteroides, Prevotella steracorrera and Gammaproteobacteria on FAP 
mucosa (n=4 patients) compared with mucosa of healthy subjects (n=10 subjects) and 
sporadic CRC (n=25 patients). (B) Trend of Bacteroides enrichment on FAP polyp mucosa, 
though not significant, when compared to Sporadic CRC (p=0.09) and healthy subjects 
(p=0.11). (C) Prevotella stercorea on FAP polyp mucosa compared with sporadic CRC 
(p=0.027) and healthy subjects (p=0.0012). (D) Gammaproteobacteria population detected by 
sequencing compared with sporadic CRC (p=0.029) and healthy subjects (p=0.016).  
















Figure 4.2. FISH and microbiology culture analysis of FAP mucosal tissues.  (A) FISH of all 
bacteria (red) biofilms on the mucosal surface of FAP polyp and paired normal tissues 
counterstained with DAPI nuclear stain (blue). The majority of the biofilm composition (B) 
was identified as B. fragilis (green) and E. coli (red) using species-specific probes. Images 
obtained at 40x magnification, scale bars 50 µm. (C) Enterobacteriaceae (yellow) and E. coli 
(red) FISH probes on paired normal FAP tissue (100x) revealing invasion of epithelial cells 
at the base of a crypt. Right panels with insets of Enterobacteriaceae (top right panel) in 
yellow, E. coli (middle right panel) in red and overlay (bottom right panel) confirming 
identification of the invasive species. Scale bar represents 20 µm. Semi-quantitative culture 
analysis (D) E. coli and (E) B. fragilis mucosal populations on mucosa of FAP patients (n=6 
patients, 14 tissue specimens) compared to control subjects (n=11 subjects, 11 tissue 
specimens).  Data displayed as colony forming units (CFU) per mm2 of tissue cultured and 














Figure 4.3 Acute colitis induced by pks+E.coli and ETBF.  (A) γ-H2AX IHC of DNA 
damage in the proximal and distal colon of wild-type mice infected with pks+E.coli (left 
panels) ETBF (middle panels) or co-infected with pks+E.coli and ETBF.  pks+E.coli DNA 
damage is detected mostly at the differentiated surface epithelium, ETBF-induced DNA 
damage is mostly detected at the base of the crypt, while co-colonized mice have 
significantly increased DNA damage throughout the crypt along the entire colonic axis. (B) 
Quantification of DNA damage displayed as percentage of positive cells per crypt (n=6 mice 
per group). (C and D) Quantitative PCR of inflammatory cytokines in distal colon of singly 
and co-infected mice, data displayed as fold increase above sham (n=5 mice per group).  (C) 
iNOS expression in the distal colon of co-infected mice when compared with mice singly 
infected with pks+E.coli.  (D) IL-1 beta expression in the distal colon of co-infected mice 
compared with mice singly infected with ETBF or pks+E.coli. p-values were calculated with 


































Figure S4.1. FISH of all bacteria (red) on colon specimens collected from an individual with 
FAP.  Tissue specimens were collected approximately every 3-5 centimeters starting in the 
right colon (sample 1) and ending in the rectum (sample 15).  Patchy biofilms detected 












Figure S4.2 Biofilm characterization of FAP colons.  Specimens from six prospectively 
collected FAP colons were available for FISH analysis.  Four individuals (3775, 3975, 3995 
and 3971) contained a bioifim, while the JP and antibiotic treated patient had no biofilms. 
FISH of all bacteria top panels, displaying representative biofilms from each patient and 
species specific FISH probes (below) of E. coli and B. fragilis biofilm composition from each 
























































Figure S4.3 Histopathology of acute colitis induced by pks+E.coli isolates. H&E stained 
distal colon of wild-type mice seven days post-inoculation. Variable colitis was detected 
among the strains with increasing pathology from NC101< isolate1< isolate2< isolate3. A 















































A modified version of this Chapter is published in: Dejea C, Wick E, Sears CL.  Bacterial 
oncogenesis in the colon.  Future Microbiology. 2013; 8(4), 445-460.   
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Sporadic colorectal cancer is ultimately a genetic disease, where gene alterations and 
chromosomal instability are central to the stepwise progression towards neoplasia [4,5].  This 
complex process is undoubtedly the result of numerous influences ranging from age, gender, 
nutritional intake, physical activity and host genetic background, to the diverse and variable 
colonic microbiome. Epidemiological and experimental evidence discussed here strongly 
suggest a role for several bacterial agents in CRC. However, traditional bacteriological 
approaches are built on the assumption that an etiologic pathogen can be isolated, cultured 
and identified, and that pathogenesis can be explained through confirmation of disease.  
Throughout the 19th century and beyond, these concepts, grounded in Koch’s postulates, 
have proven to be crucial in the identification of countless infectious pathogens, including 
the etiologic agent of gastric cancer, H. pylori [197].  Yet unlike the archetypal infectious 
disease consisting of a single causative agent, the colon houses a variety of commensal 
organisms, many of which have been implicated, both alone and in consort, to contribute to 
the genesis of colon cancer. The challenge of traditional epidemiological approaches to 
identify links between bacterial agents and CRC is further hampered by the long length of 
time between initiation and detectable carcinogenesis. Searching for the responsible agent(s) 
among the multiple constituents of the colonic flora presents a challenging prospect, since it 
is possible that the critical inciting microbial agent or composition is no longer present at the 
time of disease discovery.  As such, we are then potentially reliant on detection of an 
immune signature to the microbe or microbiota to provide the epidemiologic link to CRC. 
The work presented in this thesis supports the potential for bacterial alpha bugs or drivers in 
the context of the aggregate flora to shape the microbial community yielding a 
procarcinogenic environment [195,196]. This emphasizes the need for detailed knowledge 
about specific microbes as well as alterations of whole microbial communities under diseased 
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and healthy states to better understand the etiology of CRC.  The advent of next generation 
sequencing technologies have facilitated these types of studies that can take into account the 
community of a specimen, many of which were discussed here (CHAPTER 1, Table 1.2).  
However, limitations in the experimental evidence to date include small sampling numbers 
and limited control populations for comparison.  Furthermore, information regarding host 
genetics is also necessary; as revealed by numerous mouse studies, commensal bacteria have 
pathogenic capabilities in the context of genetic abnormalities in the host.   
While advances have been made in the early stages of characterizing what species are present 
on tumors and their flanking tissues, the data presented here is the first attempt to determine 
the spatial organization of those microbes with respect to the host epithelium.  The spatial 
arrangement of the bacterial community dictates both microbe-microbe interactions and 
microbe-host interactions. Proximity to the host epithelium facilitates the way in which 
microbes are recognized and responded to by the host innate and adaptive immune system 
[198]. Our systematic studies of the distribution of microbes along both the length of the 
colon, as well as a cross-sectional characterization of the lumen and mucus layer members 
are essential to further elucidate the role of specific bacterial community members in the 
cancerous disease state.           
As the field moves forward, several types of evidence will be needed to link the microbiota 
to human CRC [199]. Prospectively conducted studies, initiated at a time point before the 
onset of disease, and with relevant samples (blood, tissue and stool) for analysis would be 
ideal.  Capturing information about the microbiome structure and composition in the early 
stages of disease initiation and throughout disease development would be invaluable.  
Ideally, the detection of microbiome dysbiosis or exposure to specific putative etiologic 
agents before disease development would help to address the cause or consequence 
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conundrum. However, population-based microbiome studies are both cost-prohibitive and 
impractical for evaluating long-term (20-40 years in the case of colon cancer) disease 
development.  Attention to designing control groups and using varied controls is important 
as well to help determine if a microbe or a microbiota composition exhibits a strong, 
consistent association with human CRC.  We should seek to detect an immunologic 
response to the purported microbial etiologies of CRC. It was the combined criteria of either 
detection of H pylori or an immune response to H pylori that provided crucial data to define 
H pylori as the cause of most gastric cancer [197]. Murine models of colon oncogenesis will 
likely provide key insights into molecules and mediators with translational importance to 
understanding how the microbiota contributes to human CRC. Ultimately, elimination of the 
inciting microbe or restructuring of the microbiome whether by diet, probiotics, antibiotics 
or vaccination with subsequent prevention of CRC is required for definitive declaration of 
disease association.  While these criteria are stringent and create a necessarily high bar for 
investigators to reach, there has never been more interest in understanding the microbial 
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